Published on Pfizer: the world's largest research-based pharmaceutical company (http://www.pfizer.com)

Home > Health & Wellness > Medicine Safety > Medicine Safety Education > Medicine Safety Education

Medicine Safety Education

  • Medicine Safety Education - home
  • Medicine Safety for Patients
  • Understanding Risks
  • Medicine Safety Timeline
  • Partnering to Protect Patients
Close

Looking for information about specific medicines?

There are many valuable resources available to help you learn more about the benefits and risks of specific medicines or medical treatments.

To learn more about medicines prescribed in the United States, visit:

The U.S. Food and Drug Administration (FDA) Web site
Go to FDA Drug Index

The Physicians' Desk Reference Web site
Go to www.pdrhealth.com

To learn more about a specific Pfizer medicine, visit:

The Pfizer.com Products page
Go to Pfizer Products

If you live outside the U.S., please consult your local regulatory agency for safety information about specific medicines prescribed in your country.

Medicine Safety Education

Medicine Safety Education

A resource for health care providers and patients

Part of our responsibility as a global pharmaceutical company is to help keep the patients who take our medicines safe. At Pfizer, our commitment to medicine safety begins in the research laboratory—and continues for as long as the medicine is prescribed to patients anywhere in the world.

As part of this commitment, we have developed this interactive educational section in pfizer.com to help health care providers, public health professionals, patients, and caregivers learn more about medicine safety. "Understanding Risk", "Medicine Safety Timeline", and "Partnering to Protect Patients" have been developed for professional audiences. "Medicine Safety for Patients" has helpful information developed especially for patients and caregivers.

Choose the section of the site you would like to visit by clicking on an image below.

Looking for information about specific medicines?

Medicine Safety Video Hosts   (select a section)

  • Introduction
    to Medicine
    Safety

  • Medicine Safety for patients

  • Understanding Risk

  • Medicine Safety Timeline

  • Partnering to Protect Patients

> Next: Click to Get Started

2390746951001

Welcome to our Medicine Safety Web site. This site is designed to help you learn more about the science, processes, and people involved in the work of understanding the risks and benefits of medicines.

As part of the global health care community, pharmaceutical companies work with regulatory agencies, health care professionals, and patients to understand, as precisely as possible, the risks and benefits of each medicine we develop. Information about medicine safety begins to emerge in the research laboratory—and continues to evolve for as long as the medicine is prescribed to patients anywhere in the world. That’s why there are systems and processes in place at each step to help identify and communicate benefits and risks to everyone involved in making decisions about treatment.

Throughout this site, we will help you explore these processes as well as the science behind the research and development of prescription medicines. Look for the guide in each section of the site and press play for help in navigating through the information.

 

Navigator (click to expand and view section topics) (click to close)
  • Partnering With Your Health Care Professional
  • Sharing Your Medical History
  • Getting All the Facts
  • Making Medicine Decisions
  • Videos
  • Ask Me 3 For Medicine Safety
  • Filling Your Prescription
  • Taking Your Medicine
  • Reporting Side Effects
  • Understanding Safety Updates
  • Helpful Resources
  • Helpful Links
Medicine Safety for Patients

Your Role in Medicine Safety

When it comes to taking medicine, you play an important role in ensuring your safety—and the safety of those you care for. By partnering with health professionals involved in your care, you can help them determine which medicines are most appropriate for you or your dependents. Partnering also helps your health care professionals teach you how to take these medicines safely.

In this section, you'll learn how to reduce your risks of medication safety problems at key points in your care:

  • At your doctor's visit
  • When you fill your prescription
  • When you take your medicine
  • After you take your medicine

Who plays a role in medicine safety?

  • Pharmaceutical companies that develop, test, and produce medicines
  • Regulatory agencies that approve the use of medicines—like the U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA)
  • Health care professionals who prescribe medicines
  • Pharmacists who dispense and provide counsel regarding your medicine
  • Patients and caregivers who take medicines or give medicines to those they care for

What is involved in approving a medicine?

All medicines have benefits as well as risks. Before any new medicine is approved by regulatory agencies such as the EMA or the FDA, it undergoes extensive testing—usually in several thousand people. The goal of this testing is to determine how safe and effective the medicine is—and to show that its benefits outweigh the known risks. A medicine is approved for use by appropriate patients only when its benefits have been adequately shown to outweigh the risks for its intended use in those patients.

> Next: Partnering With Your Health Care Professional

Medicine Safety Education Home

2390717973001

Medicine safety is a shared responsibility. Throughout the life of a medicine, many individuals and organizations work to ensure that the medicine is safe—from the pharmaceutical companies that develop and produce medicines, to the regulatory agencies that approve their use, and the doctors and other health care providers who prescribe them.

Before it is approved for use, a medicine must go through extensive testing. A medicine is approved for use in appropriate patients only when its benefits outweigh the known risks for its intended use in that population.

But you also play an important role in ensuring medicine safety.

By partnering with your doctors, you can help them determine which medicines are most appropriate for you or those you care for.

In this section, you’ll learn more about how to maximize medicine safety.

Click Next to continue.

Partnering With Your Doctor

Partnering With Your Health Care Professional

Your doctor, pharmacist, nurse or other professionals involved in your care can learn about the known benefits and risks of a certain medicine. But to make sure it's right for you or someone you care for, they may need to ask you for information that only you can provide.

 

You can help make your treatment plan safer by:

  • Telling your doctor about your complete health and medication history
  • Asking questions and getting the facts about your medicine
  • Seeking counsel from your pharmacist

> Next:  Sharing Your Medical History
< Previous:  Your Role in Medicine Safety

Medicine Safety Education Home

2390750583001

Health care professionals are continually learning about the known benefits and risks of medicines.

But to make sure a medicine is right for you or someone you care for, your doctor may need to ask you for information that only you can provide.

That’s why open and honest communication is essential. When you visit your doctor or other health care professional, you can help make your treatment plan safer by giving complete and accurate facts about yourself and your health, and by getting information about your treatment program, especially any new medicines you’ll be taking.

This means that at your health care visit, it’s important to tell your doctor about your health and medication history, ask questions, and get the facts about your medicine.

In this section, we’ll be focusing on the role your medical history can play, and how you can help give your doctor as complete an account of your medical history as possible.

Click Next to continue.

Sharing Your Medical History

Sharing Your Medical
History

Your medical history is the foundation upon which your doctor builds the best treatment plan for you. A detailed history helps your doctor get to know you, identify possible causes of any health conditions, and determine which—if any—treatments you may need.


Your doctor may ask you about:

  • Any symptoms you may be experiencing
  • Any medical conditions you've been diagnosed with—such as heart disease or arthritis
  • Any illnesses you have experienced—like flu or hepatitis
  • Any surgical operations you have had—such as a tonsillectomy or caesarean section
  • All medicines and treatments you are currently using
  • Anything that could affect your ability to take medicine safely or regularly
  • If your healthcare professional has not provided you with one, you can use this sheet.

What medicines should you tell your doctor about?

  • Products you take every day or just once in a while
  • Nonprescription (or over-the-counter [OTC]) medicines—such as pain relief products (including those applied to the skin), cold or allergy remedies, antacids, or laxatives
  • Prescription medicines, including samples
  • Vitamins, supplements, and herbal or natural remedies
  • If you are a female, oral contraceptives, contraceptive patches, or long-acting contraceptive injections

You should also tell your doctor about the use of:

  • Alcohol
  • Cigarettes
  • Substances such as marijuana or cocaine

Disclosing everything you take is extremely important because some medications can mix dangerously with others, even in small doses.

What can affect your ability to take medications?

  • Known allergies or sensitivities
  • Being pregnant, trying to conceive, or breast-feeding
  • Having memory problems
  • Having trouble swallowing, seeing clearly, or using your hands

> Next:  Getting All the Facts
< Previous:  Partnering With Your Health Care Professional

Medicine Safety Education Home

2390746950001

If you’re not sure what kind of information your doctor may ask you for, the first place to start may be your medical history. Your medical history is a history of all the medical conditions, illnesses, and surgeries you have had. Even things that happened long ago can be very important, so be as detailed as you can.

Your doctor or other health care professionals may also ask you about all medications and other treatments you currently use, including things like dietary supplements and medicines you can get without a prescription. And, you should mention anything that could affect your ability to take a medication safely or regularly.

Now that you’ve learned what to tell your doctor, let’s see what you should be asking, too. Click Next to continue.

Getting All the Facts

It's not unusual to feel nervous or overwhelmed when discussing important health issues with your health care professional. But remember—understanding your medical condition and treatment plan is essential to good health.


Be an active patient or caregiver

  • Prepare ahead of time—bring a list of questions with you to the appointment
  • Record the most important facts about your medicines
  • Visit Clear Health Communication's AskMe3 Web site to learn more about how to talk to your doctor. Visit www.AskMe3.org
  • You may wish to bring along a friend or relative for additional support if you wish (discuss with your healthcare provider if joining consultation)
  • Write down notes during your conversation with the doctor, nurse or pharmacist
  • Tell your health care professional if you have any communication issues—like hearing loss or English as a second language
  • Ask for clarification of anything you don't understand—and persist until you get answers that are clear to you

Considering a medicine

Before you and your doctor decide on a medicine, there are many important points you'll need to discuss. Roll over the graphic below to learn more.

To view this interactive feature, you must have Flash 9 installed on your computer.
If you do not have Flash 9, you can download it from the Adobe web site.

To view this interactive feature, you must have Flash 9 installed on your computer.
If you do not have Flash 9, you can download it from the Adobe web site.

> Next:  Making Medicine Decisions
< Previous:  Sharing Your Medical History

Medicine Safety Education Home

2390717972001

It’s not unusual to feel tense, overwhelmed, or concerned about taking too much of your doctor’s time. But being an informed patient or caregiver is essential to good health. It’s best to prepare ahead of time by writing down a list of questions you want to ask your doctor. Bring along pen and paper to jot down notes during your conversation. You may also want to bring a friend or relative along for support.

Ask for clarification of anything you don’t understand. And be sure to make your doctor aware of any communication problems you may have such as hearing loss or English as a second language—and ask questions until you get clear answers.

If you and your doctor decide you need to take medicine for a certain condition, it is important to discuss it carefully before deciding on which one is best for you.

Roll over the graphic to the left to learn about the important points you and your doctor should discuss when deciding on a medicine.

Now, let’s take a more in-depth look at the factors that may affect your, and your doctor’s, treatment decisions.

Making Medicine Decisions

Making Medicine Decisions:
Risks, benefits, and choices

When you and your doctor decide on a certain medicine, you are making a choice—one that weighs the benefits the medicine can offer to your health against the risks of side effects. Together, you will decide how much risk you are willing to accept in light of the potential benefits.


  • Learn more about medicine side effects

What level of risk is "acceptable" to doctors and patients? The answer differs for every individual—and being aware of the factors that shape perspectives on risk can help you and the health care professionals involved in your care work more effectively as a team in making treatment decisions.

Factors that may affect risk perception include:

  • Past experience (good or bad) with medicines, for yourself or a friend or family member
  • Educational level
  • Age
  • Cultural background
  • Personality (for example, optimistic versus pessimistic; eager to try new things versus prone to avoiding risk)
  • Learning style (for example, persuaded by scientific data versus more affected by personal stories and anecdotes)

> Next:  Videos
< Previous:  Getting All the Facts

Medicine Safety Education Home

2390750582001

Every product and activity, including any kind of medicine or medical procedure, involves benefits and risks. People decide how much risk they are willing to accept in light of the potential benefits they anticipate.

But what level of risk is "acceptable"? The answer differs for every individual, based on factors from age and cultural background to past experiences with medicines and learning style.

Health care professionals are also influenced by these factors in making their treatment recommendations. When you and your doctor are both aware of the personal factors that shape your perspectives on risk, you will be able to work more effectively as a team in deciding on treatments that are right for you.

Click Next to listen to stories based on real-life factors involved in medication decisions.

Making Medicine Decisions:
Videos

The decision to take a medicine is a personal one that is made jointly by a patient and doctor. Together, you and your doctor take knowledge about how a medicine affects the patient population overall, and then apply it to your individual health situation—also taking into account personal feelings, experiences, beliefs, and values.

Listen to these stories about medicine decisions based on some of the factors that affect patients' real-life choices. You may recognize some of the same reasons and concerns that you feel when making decisions about medicine.

Remember, there is no single right answer for every person or situation—be sure to discuss your personal decisions about medication with your doctor.

 

Diagnosis: High Blood Pressure

 

To view this interactive feature, you must have Flash 9 installed on your computer.
If you do not have Flash 9, you can download it from the Adobe web site.

Colin, 55

Diagnosis: High blood pressure

  • 2390746949001

    Colin, 55

  • 2390750581001

    Ben, 54

Diagnosis: Osteoarthritis

  • 2390746948001

    Dan, 65

  • 2390717970001

    Elena, 62


Diagnosis: ADHD

  • 2390750580001

    Jenna, 7 (and her mom, Peggy)

  • 2390746947001

    Tyler, 8 (and his mom, Kathy)






> Next:  Filling Your Prescription
< Previous:  Making Medicine Decisions

Medicine Safety Education Home

2390717971001

The decision to use a particular medicine should come from a doctor/patient discussion that carefully weighs the potential benefits and risks for that individual.

Press play to listen to stories about medicine decisions based on some of the factors that affect patients’ real-life choices.

Then, click Next to learn how you can work with your pharmacist to help keep yourself—and your family—safe when taking medicines.

Ask Me 3 For Medicine Safety

Good Questions for Your Good Health

Do you know...The name of your medicine? What it is used for? How to take it? The side effects?

If you answered no to any of these questions, you are not alone. Many patients leave their doctor's office or pharmacy without the information they need to take their medicine properly and safely.

Pfizer Inc., in partnership with the National Patient Safety Foundation (NPSF), has created a resource, Ask Me 3 For Medicine Safety, that will help you get the information you need to take your medicine properly and safely. Click here to download a PDF that lists questions to ask your doctor, nurse, or pharmacist at your next visit.

Ask Me 3 For Medicine Safety builds upon the success of the Ask Me 3 program that was created to help you have a better conversation with your health care provider. Click here to download a PDF that will help you learn more about Ask Me 3.

The National Patient Safety Foundation is an independent non-profit organization. Its mission is to improve the safety of patients. NPSF joined forces with the Partnership for Clear Health Communication (PCHC). Together, their main focus is helping patients and health care providers communicate even better, for better health.

  • Download the Ask Me 3 For Medicine Safety PDF
  • Download the Ask Me 3 For Medicine Safety PDF en Español

Medicine Safety Education Home

No_video
 
Filling Your Prescription

Filling Your Prescription

Your pharmacist is a valuable partner in your care. To help keep you and your family safe, always take these steps when filling a prescription for yourself or someone you care for:

  • Make sure you have the right medicine and dosage—and that you understand how to take the medicine—before leaving the pharmacy
  • Download tips to reduce your risk of medication errors
  • Find out the active ingredient of any nonprescription medicine—and avoid taking more than one kind of medicine containing that ingredient
  • Ask your pharmacist to explain anything that is unclear
  • Make the most of your pharmacist's expertise

Reading the label

The label on your prescription contains important information to help you take your medicine safely. Roll over the bottle below to learn more about medicine labels.

To view this interactive feature, you must have Flash 9 installed on your computer.
If you do not have Flash 9, you can download it from the Adobe web site.

> Next:  Taking Your Medicine
< Previous:  Videos

Medicine Safety Education Home

2390717969001

When you fill a prescription for medicine, for yourself or someone you take care of, make sure you take advantage of a valuable partner in your care—your pharmacist—and make sure to read the label on your prescription.

It may sound obvious, but many people ignore the instructions or warnings that come with their medications. Or they may be confused about the directions or the sticky labels on their pill bottles, and never bother to get answers.

Rollover the image of the pill bottle to the left to learn about the important information included on your prescription label.

And remember—anytime you’re uncertain about information concerning your medicine, ask your pharmacist or doctor.

Click Next to continue learning how you can take medicine safely.

Taking Your Medicine

Taking Your Medicine

Your role in medicine safety continues after you take your medication home from the pharmacy. Each time you take your medicine—or give medicine to someone you care for—you are playing a key role in ensuring your safety and the safety of those in your care.

Take your medicine (or, as a caregiver, give it to the patient) exactly as directed:

  • Read the directions and special instructions on your medicine, every time you take it
  • Follow the directions on the label along with any other instructions from your health care team
  • Do not change the usual daily dosage without talking to your doctor first
  • Store the medicine according to any instructions provided, and be sure to keep it out of the reach of children and pets

> Next:  Reporting Side Effects
< Previous:  Filling Your Prescription

Medicine Safety Education Home

2390750579001

Your role in medicine safety continues after you take your medication home from the pharmacy.

Each time you take your medicine, or give medicine to someone you care for, read all of the directions and special instructions. Follow the directions on the label along with any other instructions from your health care team.

It's also important not to change the dosage without talking to your doctor first. Some medications don’t make you feel better right away and some need to be taken even after you feel better. With some medications, if you and your doctor decide that you should stop taking them, you may need to stop gradually.

There's one more important step in ensuring medication safety—recognizing and reporting any problems that might be related to the medicines you take. Click Next to learn more.

Reporting Side Effects

Reporting Any Side Effects

"Report any side effects to your doctor or another health care professional right away."

One of the most important things you can do to keep yourself and those you care for safe is to promptly recognize and report any problems that might be related to the medication. Here's how:

  • Be alert to how you feel after starting the medication
  • Report any side effects to your doctor or another health care professional right away. For side effects that seem severe, such as difficulty breathing, extreme dizziness, or a very bad rash, contact emergency services
  • For parents and caregivers: Download these helpful guides to learn more about medication safety for children and seniors
  • Medication safety for children: A guide for parents and caregivers
  • Medication safety for the elderly: A guide for patients and caregivers

> Next:  Understanding Safety Updates
< Previous:  Taking Your Medicine

Medicine Safety Education Home

2390750584001

One of the most important things you can do to keep yourself and those you care for safe is to promptly recognize and report any unwanted effects that might be related to the medication.

Be alert to how you feel after starting the medication, and tell your doctor or other health care professional right away if you think you may be having any unwanted effects from it. You may need a different dose or a different kind of medication.

If you are caring for a child or elderly person, you will also need to be aware of special challenges and concerns relating to the safety of medication for both old and very young patients.

Download our guides to learn more about medication safety for children and seniors.

Understanding Safety Updates

Understanding Safety Updates

A medicine is approved for use in patients only when extensive testing shows that its benefits outweigh the risks for its intended use. But, sometimes safety issues may arise even after a medicine is approved, as it is used by greater numbers of people with more varied backgrounds than those involved in clinical studies.

Pharmaceutical companies and regulatory agencies, such as the U.S. Food and Drug Administration (FDA), act promptly to address all credible information about emerging medicine safety issues. These organizations work together to:

  • Analyze the available evidence
  • Communicate findings to health care professionals and the general public
  • Continue to monitor additional information
  • Take appropriate action as required

Taking action in response to emerging safety information

When learning about the action taken by regulators and pharmaceutical companies in response to emerging safety information, it can be hard to know what it means for individual patients. That's because different information requires different actions. For example:

  • Changes may be made to the professional Prescribing Information.
    Learn more
  • Letters may be sent out to health care professionals.
    Learn more
  • A special strategy to manage the risks, known as a Risk Evaluation and Mitigation Strategy (REMS), or an update to an existing REMS, may be required.
    Learn more
  • Information may be issued by regulatory agencies.
    Learn more
  • A batch of product may be recalled.
  • New clinical studies may be planned.

> Next:  Prescribing Information Changes
< Previous:  Reporting Side Effects

Medicine Safety Education Home

2390750585001
 

Changes to a Medicine's Professional Prescribing Information

Sometimes, when new safety information arises about an approved medicine, changes must be made to the professional Prescribing Information—designed to help health care providers use the medicine safely and effectively.

Roll over the graphic below to learn more about some of the sections of the professional Prescribing Information most commonly changed in response to new safety information.

To view this interactive feature, you must have Flash 9 installed on your computer.
If you do not have Flash 9, you can download it from the Adobe web site.

  • Learn more about product labeling

Click here to see monthly summaries of safety labeling changes approved by the FDA

> Next:  Letters to Health Care Professionals
< Previous:  Understanding Safety Updates

Medicine Safety Education Home

Letters to Health Care Professionals

Letters to Health Care Professionals

In certain cases, manufacturers of a medical product may need to inform doctors, pharmacists, and other health care providers about new safety concerns that have arisen about one of their marketed medical products.

To do this, they send what are known as "Dear Health Care Professional" letters. These letters may include information about:

  • Warnings and/or Precautions added to the label
  • New data regarding significant adverse events
  • Other important information about the product

> Next:  Strategies to Manage Risk
< Previous:  Prescribing Information Changes

Medicine Safety Education Home

Strategies to Manage Risk

When new safety information emerges about a medicine, the U.S. Food and Drug Administration (FDA) may require a company to develop a Risk Evaluation and Mitigation Strategy (REMS)—or update an existing REMS—to manage these potential serious risks. The goal of a REMS is to ensure that the medicine is used appropriately so that its benefits outweigh its risks.

View the FDA's list of products with an approved REMS

Components of a REMS may include:

  • A timetable for measuring how well the REMS is working—Required for all REMS
  • A Medication Guide—A key component for many medicines, created to inform patients of the risks of a specific medicine and how to take that medicine safely. Generally, a paper handout of the Medication Guide must be given to the patient each time that medicine is dispensed to a patient or caregiver
    View the FDA's list of products that have Medication Guides
  • Additional communication, or special training, for health care professionals who prescribe or dispense the medicine
  • Special monitoring of patients who take the medicine

> Next:  Regulatory Agency Communications
< Previous:  Letters to Health Care Professionals

Medicine Safety Education Home

Regulatory Agency Communications

Regulatory Agency Communications

In addition to medicine safety information communicated by pharmaceutical companies, regulatory agencies also issue communications to keep patients and health care professionals up to date on the latest developments.

For example, the U.S. Food and Drug Administration's (FDA) Web site contains a page titled Postmarket Drug Safety Information for Patients and Providers, which serves as a portal to many different types of publically available documents concerning medicine safety issues.
Go to the FDA's Postmarket Drug Safety Information for Patients and Providers

Available documents may include:

  • Drug Safety Communications
    Learn more
  • Safety Alerts for Human Medical Products
    Learn more
  • Quarterly reports of potential medicine safety issues
    Learn more

> Next:  Drug Safety Communications
< Previous:  Strategies to Manage Risk

Medicine Safety Education Home

Safety Alerts

Drug Safety Communications

Drug Safety Communications are short FDA bulletins that are issued and updated as needed to provide public with a single source for the current "headline news" concerning the safety of a medical product.

Each Drug Safety Communication contains:

  • A Safety Announcement, including:
    —The source of new safety information (reports of side effects in patients, clinical study results, etc.)
    —The identified or potential problem
    —The actions that have been taken or are being considered, which may include:
       — Convening Advisory Committees to seek expert opinion
       — Requiring new clinical studies
       — Recalling a product
       — Adding warnings to the product label
       — Creating or updating a Medication Guide
  • Additional Information for Patients
  • Additional Information for Healthcare Professionals
  • Data Summary
  • References
  • Links to any related information

Find out whether a medicine you're taking—or consider taking—appears on the FDA's Drug Safety Communications page.

Introduced in January 2010, Drug Safety Communications replaced a range of different types of documents used previously, including:

  • Healthcare Professional Sheets
    Click here to see Healthcare Professional Sheets issued from 2005 to 2009
  • Public Health Advisories (Drugs)
    Click here to see Public Health Advisories issued up until 2009
  • Early Communications and Early Communications about Ongoing Safety Reviews

> Next:  Safety Alerts for Human Medical Products
< Previous:  Regulatory Agency Communications

Medicine Safety Education Home

Information for Health Care Professionals

Safety Alerts for Human Medical Products

The U.S. Food and Drug Administration (FDA) may issue a safety alert to inform health care professionals when new safety information is available for medicines that they prescribe or administer. These alerts may include:

  • A Drug Safety Communication
  • Safety-related labeling changes
  • Product recalls

These brief communications are organized as follows

  • Audience: The healthcare specialty for which the information is intended (e.g., Family Medicine, Oncology)
  • Issue: A brief summary
  • Background: A brief summary
  • Recommendations on handling the safety issue, such as:
    — Avoiding the use of the medicine with certain kinds of patients
    — Switching patients from the medicine in question to an alternative therapy
    — Monitoring patients for certain conditions or adverse effects when using the medicine
    — Providing patients with additional information or precautionary warnings

Find out whether a medicine you're taking—or considering taking—has any active Safety Alerts. View the FDA Drug Index

View the FDA's Safety Alerts pages

> Next:  Quarterly Reports
< Previous:  Drug Safety Communications

Medicine Safety Education Home

Quarterly Reports

Quarterly Reports

The U.S. Food and Drug Administration (FDA) stores all reports received about adverse events experienced by patients taking medicines in a single database. This database is regularly examined by the FDA staff. When a potential signal of a serious risk is identified, it is logged as a medicine safety issue. A new listing is then issued each quarter, showing newly identified Potential Signals of Serious Risks and New Safety Information Identified from the Adverse Events Reporting System.
View the FDA Quarterly Reports of Potential Safety Issues

The appearance of a medicine in this quarterly listing does not mean that the FDA has concluded that the medicine is the cause of the safety risk. It simply means that the FDA has identified a potential safety issue. It also does not mean that the FDA is suggesting that health care providers should not prescribe the medicine or that patients taking the medicine should stop taking it. Patients who have questions about their use of the identified medicine should contact their health care provider. The FDA will complete its evaluation of each potential safety issue and may take further action as appropriate.

  • Download What is a Safety Signal?

> Next:  Helpful Resources
< Previous:  Safety Alerts for Human Medical Products

Medicine Safety Education Home

Helpful Resources

A Resource Kit for Safer Medicines

Click on the links below to download resources on reducing or managing your medication risks. Keep these easy-to-print information sheets for your reference or share them with your doctor, pharmacist, or other health care professionals.


My health and medications: A fact sheet for my health care team
This tool was developed to improve the safety of patients by asking them to be partners in their care. Keep it updated and bring it to your doctor, clinic, hospital, or pharmacy. If you are a caregiver for a child or an elderly person, fill it out for them and make a copy available to other responsible or trusted people, such as day care providers, who might need it in case of emergency.

  • Download fact sheet

Avoiding medication errors
Learn simple ways to help reduce your risk of getting the wrong drug or dose. Plus, find out how to dispose of old medicines safely.

  • Download tips

Your pharmacist: A partner in drug safety
The knowledge and experience of your pharmacist can help reduce your risk from nonprescription or prescription medicines. Here's how to get the most from them.

  • Download PDF
  • For more information, visit www.pharmacist.com

Medication safety for children: A guide for parents and caregivers
Children often have special safety issues regarding medicine. This guide presents some important ones and how to handle them.

  • Download guide

Medication safety for the elderly: A guide for patients and caregivers
Older adults also often have special safety issues regarding medicine. Learn how to help manage safety for yourself or seniors you care for.

  • Download fact sheet

Understanding side effects
Gaining a better understanding of side effects can help you weigh the benefits and risks of your treatment options. Learn more about side effects so you and your doctor can choose the medicines that are right for you.

  • Download PDF

> Next:  Helpful Links
< Previous:  Quarterly Reports

Medicine Safety Education Home

2390750585001
 
Learn More

Helpful Links

The Web sites below can help you learn more about medicine safety. These Web sites are neither owned nor controlled by Pfizer. Pfizer is not responsible for the content or services of these sites.


What you need to know to use medicine safely (FDA)
Safety information for patients and health care providers (FDA)
Safety information for specific drugs (FDA)
Patient health literacy (AMA)
Consumers Advancing Patient Safety (CAPS)
SafeMedication.com (ASHP)
Tips for seniors (ASCPF)
Preventing medical errors (AHRQ)
More on safety (PhRMA)
How to dispose of unwanted or expired medicines safely
How to get the most from your pharmacist (APhA)

> Next:  Understanding Risk
< Previous:  Helpful Resources

Medicine Safety Education Home

2390750585001
 

 

Navigator (click to expand and view section topics)(click to close)
  • Perceiving Risk
  • How Risk Changes
  • Risks of Life
  • Fear vs. Reality
  • Viewing Risk
  • Comparing Risks
  • Visualizing Risk
    with Aspirin
  • Aspirin's Benefit-Risk Balance
  • Strategies for
    Evolving Risks
  • Medicine Safety
    Survey
  • Patient Health Literacy
Understanding Risk

Understanding Risk

Like many aspects of life, taking medicine involves benefits and risks. But often, the benefits that medicines provide to our health outweigh the potential risks. Learning more about risk—and how to put it in perspective—can help both patients and doctors make important decisions about health and treatment.


In this section, you will explore the fundamentals of risk:

  • Perceiving risks: Learn more about factors that affect risk perception—and why perceptions about risk may not always reflect the actual risk involved.
  • Viewing risks: Take an in-depth look into the statistics used to evaluate risk.
  • Monitoring and communicating evolving risks: Find out how pharmaceutical companies and regulators weigh benefits and risks when making decisions about medicines.

> Next: Perceiving Risk

Medicine Safety Education Home

2390963104001

We often hear about risks to our health and safety—reports of traffic accidents, news of a friend who has an illness, or an announcement of possible side effects of a medicine. Sometimes, it can be difficult to navigate through this information to determine if—and how—these risks may affect us.

The fact is that risk is involved in many aspects of our everyday lives—from driving a car to taking medicine—even familiar medicines that are widely considered safe, like aspirin. But, we continue to drive, and to take medicine, because these things also provide benefits that often outweigh their risks.

This section is designed to help you work with your doctor to learn more about risk. In this section, we will explore some fundamental questions about risk perception—as well as statistics used to compare risks and the factors that pharmaceutical companies and regulators use to make decisions for managing medicine safety issues.

Answering these questions can help both you and your doctor make important decisions about your health and treatment.

Perceiving Risk

Risk Perception Factors

Making sense of risk is a complex challenge. Perceptions of risk are based on a combination of both facts and feelings—which is why fears may not always match the facts.

Decades of research on risk perception suggest that humans fear similar things for similar reasons. Researchers have identified these "risk perception factors" to help understand why people are often more afraid of relatively small risks, and less afraid of some risks that may pose greater danger.

Roll over each factor and read below to learn more.

  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • Dread
    Some risks provoke more fear than others. Cancer is often dreaded more than heart disease, even though heart disease is a more common cause of death.
  • Control
    Feeling in control of a process—like driving a car—can make the risk seem less than it would be when one is not in control (like being a passenger on an airplane) even though flying in a plane is statistically safer than driving.
  • "Natural" or not?
    Risks created by science, industry, or technology (such as the risk of radiation from nuclear power plants) often raise sharper concern than "natural" risks (such as radiation from the sun, which is linked to 1.3 million skin cancer cases a year in the U.S.).
  • Choice
    A risk we take voluntarily seems less frightening than one imposed on us without our consent.
  • Children
    It's a powerful instinct to protect little ones from danger. Any risk to children, from lead paint to kidnapping, seems less tolerable than the same risk to adults.
  • Unfamiliarity
    A newly discovered or reported risk (like avian or "bird" flu) may seem more alarming than a familiar one (like seasonal influenza, which affects many more people each year). With more experience and knowledge, the public can put the risk in better perspective.
  • Awareness
    When something raises our awareness about a risk—for example, heavy media coverage of a rare event like a multiple shooting—it also raises the level of concern.
  • Can it happen to me?
    Any risk can seem too big if you think that you or someone you care about could be affected. This is why numbers don't always allay people's fears: Even a one-in-a-million risk may feel important if you believe you could be that one in a million.
  • The benefit-risk balance
    If we can see a benefit in a choice or behavior, the risk may seem smaller; if less benefit is seen, the risk may seem larger. For example, we may be more willing to accept severe nausea with a life-saving cancer medicine than with an antihistamine.
  • Trust
    The less we trust the people or organizations that are charged with protecting us, or that expose us to a risk in the first place, the more concern we feel.

> Next:  How Risk Changes
< Previous:  Understanding Risk

Medicine Safety Education Home

Source: Ropeik D, Slovic P. Risk communication: a neglected tool in protecting public health. Risk in Perspective [serial online]. June 2003;11:1-4. Available from: Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, Mass. Accessed October 17, 2011.

2390750588001

Today, the world can seem like a dangerous place with widely reported threats to health, the environment, or national security. In other ways, it seems safer than ever, thanks to improved treatments for diseases such as cancer, HIV and heart disease—and safety innovations like air bags and infant car seats. Perception of risk is based on both facts and feelings—which is why the public’s fears may not always match the facts.

Decades of research on risk perception suggest that humans fear similar things for similar reasons. Researchers have identified these “risk perception factors” to help understand why people are often more afraid of relatively small risks, and less afraid of some risks that may pose greater danger.

Roll over each factor to learn more.

Then click Next to continue.

How Risk Changes

What's known about a risk itself can change over time, and the effect of that risk can vary from person to person. Some risks may be difficult to assess—even by scientists—and they must be weighed against benefits.

Roll over each image and read below to learn more.

  •  
  •  
  •  
  • Building knowledge over time
    Ongoing research may reveal that a certain activity, food, or medicine carries more or less risk than previously thought, resulting in revisions or changes to recommendations about those risks. This can make it look as if "the experts are always changing their minds" about risk. In reality, it reflects the way science works, gathering and analyzing new information and putting it to work.
  • Risk differs among individuals.
    One's personal risk from a given medicine, food, or activity may vary because of age, other medical problems, or genetic factors. For medicines, a doctor or pharmacist can help patients understand how a medicine's benefit-risk profile applies to individual circumstances (e.g., coexisting conditions and diseases, or other medicines he or she may be taking).
  • Scientists face uncertainty, too.
    Some things that are "good for you" may also carry risk, such as eating fish (which can be healthy for the heart but may contain pollutants such as mercury). Even the "experts" find it challenging to weigh benefits and risks for complex health issues.

> Next:  Risks of Life
< Previous:  Perceiving Risk

Medicine Safety Education Home

Source: Ropeik D, Slovic P. Risk communication: a neglected tool in protecting public health. Risk in Perspective [serial online]. June 2003;11:1-4. Available from: Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, Mass. Accessed October 17, 2011.

2390746954001

Risk is never set in stone. What’s known about a certain risk can change over time, and the effect of that risk can vary from one person to the next. In addition, some risks may be difficult to assess—even by scientists—and they must be weighed against large benefits.

Roll over the images to the left to learn more about the changing nature of risk.

Then click Next to continue learning about risk perception.

Risks of Life

What is the lifetime chance of a U.S. resident dying from a particular cause? Test your risk knowledge by dragging each cause into the rectangle you think matches the risk of death. You may be surprised by the answers.

To view this interactive feature, you must have Flash 9 installed on your computer.
If you do not have Flash 9, you can download it from the Adobe web site.

Get a quick refresher in statistics >

> Next:  Fear vs. Reality
< Previous:  How Risk Changes

Medicine Safety Education Home

Sources: National Safety Council, 2007 data; American Heart Association

Close

The risk of "1 in 7" in the graphic for example, means that 1 in 7 people will eventually die of a certain cause. But a risk of "1 in 88" means that only 1 in 88 people will die of a certain other cause. And, since 7 x 12 is 84, the "1 in 7" risk is over 12 times more than the "1 in 88" risk.

2390746955001

Many people have fears of specific things or activities—such as flying in an airplane. While these fears are completely understandable, they may not always reflect reality when it comes to the actual chances of harm.

Find out if your perceptions of risks match the reality of statistics. See if you can match the causes of death listed here to the risks. Some are common, others are relatively rare—can you guess which is which?

Fear vs. Reality

Remember, risk perception is a combination of logic and feelings. Roll over the images below to find out how people's worries don't always match up to real-life statistical odds of harm—and how they may ignore the more obvious benefits involved.


  •  
  •  
  •  
  • Fear: Plane crash.

    Reality: Air travel is many times safer than auto travel in both raw numbers of deaths and in annual deaths per passenger mile traveled.

    Benefit: Rapid, long-distance transportation to see family and friends, visit new places, or do business.

  • Each year, more than 36,000 Americans die in motor vehicle accidents (compared to fewer than 600 deaths in air transport accidents).
  • Each year, more than 400,000 Americans die from cigarette smoking, yet over one-fifth of all Americans continue to smoke.




     
  • Fear: Side effects.

    Reality: Serious side effects from most prescription medicines are generally rare, when they are prescribed and taken correctly; new medicines are not approved unless benefits outweigh risks in clinical studies of the intended patient population. The risks of the underlying disease may outweigh the risks of the medicine.

    Benefit: Reduction of disease or risk factors, easing of symptoms, or improvement of function.

  • Being overweight or obese poses serious health risks, including the risk of coronary heart disease, which can lead to heart attack. Approximately 80 million adults in the U.S. are overweight and another 80 million are obese, putting a very large number of people at risk.
  • Coronary heart disease is the leading cause of death in the U.S., killing some 400,000 Americans each year; taking medications to help control certain risk factors can lower risk of heart attack.


> Next:  Viewing Risk
< Previous:  Risks of Life

Medicine Safety Education Home

2390963108001

Now that you’ve learned about some common—and not so common—risks of death, take a look into the minds of others to see how they perceive these risks. Remember, risk perception is a combination of both logic and feelings. That’s why people’s worries don’t always match up to the real-life statistical odds of harm—and it’s why people may ignore the obvious benefits of activities they perceive as risky.

Roll over the images to the left to learn more.

Then click Next to learn about how you view risk.

Viewing Risk

Information about risks can be expressed in many different ways—from visualizations to numerical odds to percentages. Compare the presentations of risk below to see which you understand best.

The next time you are discussing medicine risks, ask your doctor to help you visualize the numbers in a way that helps you fully understand the information.

To view this interactive feature, you must have Flash 9 installed on your computer.
If you do not have Flash 9, you can download it from the Adobe web site.

> Next:  Comparing Risks
< Previous:  Fear vs. Reality

Medicine Safety Education Home

2390750591001

Information about risk can be expressed in many different ways. In the prescribing information, the safety profile of a medicine is most commonly presented in terms of percentages of clinical study patients who experience specific adverse events while receiving a medicine, compared with those receiving another treatment or placebo.

The frequency of adverse events may also be described using numerical frequencies such as 1 in 10 or 1 in 10,000. Take a look at some of the different ways risk information can be presented. Which do you find the clearest to understand? The next time you are discussing medicine risks, ask your doctor to help you visualize the numbers in a way that helps you fully understand the information.

Click Next to learn about comparing risks.

Comparing Risks

When discussing medicine safety, it often helps to compare the risk of a specific adverse event in those who take a specific medicine versus those who do not take that medicine. We then look at the benefits of the medicine and ask whether they outweigh the additional risk.

There are two basic ways to compare risks:

  • Comparing the difference between the absolute risks
  • Comparing the risks in proportion to one another (called relative risk)

Roll over the images below to see how different the interpretation of these statistics can be, depending on whether the risk of a particular adverse event is common or rare.

Example 1: A rare event such as a severe skin reaction or acute liver damage

Suppose for a hypothetical event, Event X occurs in 1 in 10,000 of the general population. Taking Medicine Y (for its known beneficial effects) doubles the risk of the event, which sounds high. This "doubling" of the risk (or 100% increase in risk) is called the relative risk. But what is the absolute risk from taking the medicine? The new risk is 2/10,000, which is still very low, and means that for every 10,000 patients treated with Medicine Y, there will be one extra case of Event X.

To view this interactive feature, you must have Flash 9 installed on your computer.
If you do not have Flash 9, you can download it from the Adobe web site.

Example 2: A more commonly occurring adverse event such as gall bladder disease

Now let's look at another hypothetical example of a more commonly occurring adverse event.

Over a 20-year period, approximately 10% of women participating in an epidemiological surveillance study reported suffering from Disease B. After adjusting for other risk factors, it was estimated that use of antihypertensive Medicine A conferred a 16% increase in risk for Disease B.

This sounds relatively modest compared with the 100% increase in the previous example. But if the rate of Disease B in the general population of older women is 1 in 10 (for example, 1,000 in 10,000), then this rate may increase to 1,116 in 10,000 for users of Medicine A. This represents an increase of 116 cases per 10,000 patients treated—which sounds considerable compared with the one extra case in our previous example.

However, this potential risk must be weighed against the proven benefits of the medicine in reducing complications of high blood pressure, such as heart attack.

It is also important to understand that the observations in the epidemiological study do not prove that Medicine A was the cause of Disease B. Other plausible reasons for the association include the fact that women prescribed Medicine A visited their doctor more frequently, leading to increase in a detection of Disease B.

To view this interactive feature, you must have Flash 9 installed on your computer.
If you do not have Flash 9, you can download it from the Adobe web site.

> Next:  Visualizing Risk with Aspirin
< Previous:  Viewing Risk

Medicine Safety Education Home

2390746957001

So far, we’ve been considering absolute risks—such as “1 in 100” or “1 in 10,000.” But when discussing medicine safety, it often helps to compare the risk of a specific adverse event in those who take a medicine versus those who do not take that medicine. We then look at the benefits of the medicine and ask whether they outweigh the additional risk.

There are two basic ways to compare risks—we can either look at the difference between the absolute risks or we can consider the risks in proportion to one another, which is called relative risk. The interpretation of these statistics can be very different, depending on whether the risk of a particular adverse event is common or rare in the general population.

Click on the images to the left to take a look at some examples of risk comparison.

Then click next to continue.

Close

Background Information on Low-Dose Aspirin

Low-dose aspirin is one of the most widely known—and commonly used—medicines in the world. The effects of aspirin on the body may have both health benefits and risks:

Benefits:
Aspirin helps to reduce the ability of the blood to clot. This, in turn, may help to lower the risk of cardiovascular events, like heart attack or stroke, in certain individuals.

Risks:
The same anticlotting mechanism that provides aspirin's cardiovascular benefits may also raise a person's risk of bleeding, ulceration, and perforation of the gastrointestinal tract (stomach and intestine). This risk increases when aspirin is taken in higher doses.

Low-dose aspirin has been clearly shown to reduce the risk of second heart attacks and strokes in people who have already suffered those types of events. But, it is not clear whether aspirin offers similar benefits to apparently healthy people. Researchers have studied the benefits and risks of aspirin in tens of thousands of people over several years. Close this window to explore some of these studies, which illustrate how the benefits and risks of even this well accepted medicine must be carefully considered for each individual.

Visualizing the Benefits and Risks
of Low-Dose Aspirin

One way to visualize risk is to look at the results of scientific studies of patients' experiences with a medicine. Even with a well-accepted medicine such as low-dose aspirin, the picture can be quite different depending on the types of patients studied and how the information is analyzed.



Background Information on Low-Dose Aspirin

Click below to visualize the benefit-risk balance of aspirin
in different groups of individuals.

  • Studies of High Risk Patients: A combined analysis of 6 studies in people who have suffered a previous vascular event.
    Review the study
  • The Physicians' Health Study: A study of over 10,000 male physicians
    in the U.S.
    Review the study
  • The Women's Health Study: A study of nearly 20,000 female health care providers in the U.S.
    Review the study


This information is intended only for health care professionals in the United States and is provided only for informational purposes. This information is intended to provide an example of the risks and benefits of a particular medicine. This page does not provide medical advice regarding the use of low-dose aspirin. The FDA has determined that cardiovascular indications for aspirin require the supervision of a physician (or other practitioner licensed to prescribe medicines) to ensure safe use. Patients should consult with their doctors or prescribing health care professional when considering using aspirin for cardiovascular indications.


> Next:  Aspirin's Benefit-Risk Balance
< Previous:  Comparing Risks

Medicine Safety Education Home

2390963107001
 

Visualizing Risk: People with
Prior Vascular Events

Each dot in the graph represents a person. In this example, there are 10,000 dots representing 10,000 patients who have had a heart attack, a history of angina, a stroke, or a "ministroke."

To view this interactive feature, you must have Flash 9 installed on your computer.
If you do not have Flash 9, you can download it from the Adobe web site.

This analysis combines results from 6 studies involving a total of 6,300 patients.

Goal

 

To compare the benefits of low-dose aspirin (50 to 325 mg daily) with the potential risk of gastrointestinal bleeding in patients who have previously experienced one of the following:

  • Heart attack
  • History of angina
  • Stroke
  • Ministroke

Study results

Benefit of reduced vascular events

On average, across the studies:

  • 19% of people who took low-dose aspirin experienced a vascular event.
  • 24% of people who took a placebo (sugar pill) experienced a vascular event.

Risk of gastrointestinal bleeding

In the 5 studies that reported on this risk:

  • 1.6% of people who took low-dose aspirin experienced gastrointestinal bleeding (41 cases in 2,512 patients).
  • 0.7% of people who took a placebo (sugar pill) experienced gastrointestinal bleeding (17 cases in 2,549 patients).

What do these results mean?

For every 10,000 high-risk patients who take low-dose aspirin, we would expect a subsequent vascular event to be prevented in 542.

Out of that same group of 10,000, we would expect 90 additional patients to experience a significant gastrointestinal bleed (relative to a similar group who were not taking aspirin).

Comparison of benefits vs. risks

Based on these studies, for high-risk patients, the benefits of taking aspirin in terms of preventing a further vascular event are about 6 times greater than the increased risk of suffering a significant gastrointestinal bleed.

Learn more about risk in different populations

  • View The Physicians' Health Study results
  • View The Women's Health Study results
  • Find out why results differ between studies

This information is intended only for health care professionals in the United States and is provided only for informational purposes. This information is intended to provide an example of the risks and benefits of a particular medicine. This page does not provide medical advice regarding the use of low-dose aspirin. The FDA has determined that cardiovascular indications for aspirin require the supervision of a physician (or other practitioner licensed to prescribe medicines) to ensure safe use. Patients should consult with their doctors or prescribing health care professional when considering using aspirin for cardiovascular indications.


> Next:  Aspirin's Benefit-Risk Balance
< Previous:  Visualizing Risk with Aspirin

Medicine Safety Education Home

Visualizing Risk: The Physicians' Health Study

Each dot in the graph represents a person. In this example, there are 10,000 dots representing 10,000 male physicians in the United States.

To view this interactive feature, you must have Flash 9 installed on your computer.
If you do not have Flash 9, you can download it from the Adobe web site.

In the Physicians' Health Study, over 10,000 male physicians in the United States who took low-dose aspirin (325 mg every other day) were followed for an average of 5 years and compared with a similar number who took a placebo (sugar pill).

Goal

To study the cardiovascular benefits of low—dose aspirin (325 mg every other day) in relatively healthy males. The risk of ulcers-erosions of the gastrointestinal tract often leading to bleeding and perforation—was also studied.

Study results

Benefit of fewer heart attacks

  • About 1.27% of men who took aspirin at this dose suffered a heart attack.
  • About 2.20% of men who took a placebo (sugar pill) suffered a heart attack.

Risk of gastrointestinal ulcer

  • About 0.85% of men who took low-dose aspirin suffered a gastrointestinal ulcer.
  • About 0.69% of men who did not take low-dose aspirin suffered a gastrointestinal ulcer.

What do these results mean?

For every 10,000 men who took low-dose aspirin, a heart attack was prevented in 92. Out of that same group of 10,000, 16 more men than expected experienced a gastrointestinal ulcer.

Comparison of benefits vs. risks

Based on these studies, for male patients, the benefits of aspirin in terms of preventing a cardiovascular event are about 6 times greater than the increased risk of experiencing a gastrointestinal ulcer.

Learn more about the use of aspirin in cardiovascular prevention for men

  • Review the US Preventive Services Task Force's (USPSTF) recommendations on the use of aspirin for the prevention of cardiovascular disease based on the evidence from this and other studies
    View recommendations

Learn more about risk in different populations

  • View results of studies in high-risk patients
  • View The Women's Health Study results
  • Find out why results differ between studies

This information is intended only for health care professionals in the United States and is provided only for informational purposes. This information is intended to provide an example of the risks and benefits of a particular medicine. This page does not provide medical advice regarding the use of low-dose aspirin. The FDA has determined that cardiovascular indications for aspirin require the supervision of a physician (or other practitioner licensed to prescribe medicines) to ensure safe use. Patients should consult with their doctors or prescribing health care professional when considering using aspirin for cardiovascular indications.


> Next:  Aspirin's Benefit-Risk Balance
< Previous:  Visualizing Risk with Aspirin

Medicine Safety Education Home

USPSTF Recommendations for Aspirin for the Prevention of Cardiovascular Disease in Men

  • The USPSTF recommends the use of aspirin for men age 45 to 79 years when the potential benefit due to a reduction in myocardial infarctions outweighs the potential harm due to an increase in gastrointestinal hemorrhage.
  • Tools are available to help ascertain an individual's risk for coronary heart disease as an aid to shared decision-making about the benefits and risks of an aspirin regimen.
  • The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of aspirin for cardiovascular disease prevention in those 80 years or older because the incidences of myocardial infarction and gastrointestinal bleeding both increase greatly with older age.
  • The USPSTF recommends against the use of aspirin for myocardial infarction prevention in men younger than 45 years, because their risk for heart attack is so low.

> Next:  Aspirin's Benefit-Risk Balance
< Previous:  Visualizing Risk with Aspirin

Medicine Safety Education Home

Visualizing Risk: The Women's Health Study

Each dot in the graph represents a person. In this example, there are 10,000 dots representing 10,000 female health professionals.

To view this interactive feature, you must have Flash 9 installed on your computer.
If you do not have Flash 9, you can download it from the Adobe web site.

Cardiovascular disease—including heart attack and stroke—is the leading cause of death in women as well as in men. However, several studies of the potential benefits of aspirin in preventing these diseases were conducted exclusively in men, making it important to collect information about women as well.

In the Women's Health Study, almost 20,000 female health professionals took low-dose aspirin (100 mg every other day) for 10 years and were compared with a similar number of women who took a placebo (sugar pill).

Goal

To study the potential cardiovascular benefits of low-dose aspirin (100 mg every other day) in relatively healthy females. The risk of gastrointestinal bleeding was also studied.

Study results

Benefit of fewer cardiovascular events in some groups

In the study:

  • 2.39% of women who took low-dose aspirin experienced a first major cardiovascular event.
  • 2.62% who took a placebo (sugar pill) experienced a first major cardiovascular event.

Risk of gastrointestinal bleeding

  • 0.64% of women who took low-dose aspirin experienced gastrointestinal bleeding significant enough to require a blood transfusion.
  • 0.46% of women who took a placebo (sugar pill) experienced gastrointestinal bleeding significant enough to require a blood transfusion.

What do these results mean?

Cardiovascular benefit

For every 10,000 women who took aspirin at this dose, a first major cardiovascular event may have been prevented in 23 women. This difference, however, is "not statistically significant," which means it is so small that it could have arisen by chance.

Further analysis reveals that:

  • The overall reduction in the number of strokes was significant, but the reduction in the number of heart attacks was not.
  • Women age 65 years and older comprised 10% of the study population, but experienced one third of the cardiovascular events. For this group, aspirin significantly decreased the risk of heart attack as well as stroke.

Gastrointestinal risk

For that same group of 10,000, 18 more women than expected experienced a significant gastrointestinal bleed.

Comparison of benefits vs. risks

The overall risk of cardiovascular events for the women studied was very low. As a consequence, the cardiovascular benefits and gastrointestinal risks were approximately equal.

Learn more about the use of aspirin in cardiovascular prevention for women

  • Review the American Heart Association's (AHA) recommendations on the use of aspirin for the prevention of cardiovascular disease in women based on the results of this study.
    View recommendations

Learn more about risk in different populations

  • View results of studies in high-risk patients
  • View The Physicians' Health Study results
  • Find out why results differ between studies

This information is intended only for health care professionals in the United States and is provided only for informational purposes. This information is intended to provide an example of the risks and benefits of a particular medicine. This page does not provide medical advice regarding the use of low-dose aspirin. The FDA has determined that cardiovascular indications for aspirin require the supervision of a physician (or other practitioner licensed to prescribe medicines) to ensure safe use. Patients should consult with their doctors or prescribing health care professional when considering using aspirin for cardiovascular indications.


> Next:  Aspirin's Benefit-Risk Balance
< Previous:  Visualizing Risk with Aspirin

Medicine Safety Education Home

American Heart Association Guidelines for Cardiovascular Disease Prevention in Women

The American Heart Association (AHA) has issued guidelines for the use of aspirin for the prevention of cardiovascular events specifically in women. These guidelines were created based on the results of The Women's Health Study.

The AHA guidelines are as follows:

  • Healthy women less than 65 years of age—Routine use of aspirin to prevent heart attack is not recommended
  • Women less than 65 years of age at risk of stroke—Consider aspirin therapy (81 mg daily or 100 mg every other day) when the benefit for preventing the type of stroke due to blockage of arteries in the brain is likely to outweigh adverse effects of therapy
  • Women age 65 years and older—Consider aspirin therapy (81 mg daily or 100 mg every other day) if blood pressure is well controlled and the benefit for preventing heart attack and/or the type of stroke due to blockage of arteries in the brain is likely to outweigh the risk of gastrointestinal bleeding and the type of stroke due to bleeding in the brain
  • High-risk women (such as those with diseases of the heart or blood vessels)—Aspirin therapy (75 to 325 mg daily) should be used unless contraindicated

This information is intended only for health care professionals in the United States and is provided only for informational purposes. This information is intended to provide an example of the risks and benefits of a particular medicine. This page does not provide medical advice regarding the use of low-dose aspirin. The FDA has determined that cardiovascular indications for aspirin require the supervision of a physician (or other practitioner licensed to prescribe medicines) to ensure safe use. Patients should consult with their doctors or prescribing health care professional when considering using aspirin for cardiovascular indications.


> Next:  Aspirin's Benefit-Risk Balance
< Previous:  The Women's Health Study

Medicine Safety Education Home

Differing Study Results in The Physicians'
Health Study and The Women's Health Study

Why were the results of these two studies so different?

  1. One study was conducted in men, the other in women:
    • Women's bodies handle aspirin differently than do men's bodies.
    • Gender—based differences exist in cardiovascular structure, function, and disease processes—for example, women have smaller coronary arteries, different electrical activity, and dissimilar patterns of atherosclerosis (fatty deposits in arteries).
    • Women have a greater proportion of strokes compared with heart attacks, whereas men have a greater proportion of heart attacks compared with strokes.
  2. The studies were conducted during different time periods:
    • The Physicians' Health Study was conducted from 1982-1988, while The Women's Health Study was conducted from 1993-2004.
    • People have become increasingly more health conscious over the past 25 years.
  3. Different alternate-day dosages were used in the two studies:
    • A dose of 325 mg was used for The Physicians' Health Study, while a 100 mg dose was used for The Women's Health Study.
    • The lower dose was selected in The Women's Health Study in an effort to reduce the occurrence of side effects.

Learn more about risk in different populations

  • View results of studies in high-risk patients
  • View The Physicians' Health Study results
  • View The Women's Health Study results

This information is intended only for health care professionals in the United States and is provided only for informational purposes. This information is intended to provide an example of the risks and benefits of a particular medicine. This page does not provide medical advice regarding the use of low-dose aspirin. The FDA has determined that cardiovascular indications for aspirin require the supervision of a physician (or other practitioner licensed to prescribe medicines) to ensure safe use. Patients should consult with their doctors or prescribing health care professional when considering using aspirin for cardiovascular indications.


> Next:  Aspirin's Benefit-Risk Balance
< Previous:  Visualizing Risk with Aspirin

Medicine Safety Education Home

Weighing the Benefits and Risks of Aspirin for Each Individual

Studies such as those described on the previous pages suggest that the benefit-risk balance for aspirin differs with individual circumstances:

  • Aspirin has a clear benefit in people with a current or past history of cardiovascular disease.
  • Aspirin is also likely to benefit those at moderate to high risk of having a cardiovascular event in the future.
  • There is evidence from individual controlled trials that, overall, aspirin may be more beneficial in men for preventing cardiovascular events (such as heart attack) than in women but offer better protection to women compared with men against the type of stroke caused by a blood clot.
  • However, authors of a recent analysis conducted in Europe combining results from several studies, including the U.S. Physicians' and Women's Health Studies, concluded that aspirin was of "uncertain net value" in patients "without previous disease." Others have argued that this was because the gender-specific benefits tended to cancel one another out once data for men and women were combined.
  • (Clinical guidelines suggest that the threshold at which the benefits of aspirin begin to outweigh the risks is in men who have a 6 to 10 percent chance of having a cardiovascular event within the next 10 years.)
  • The benefits of aspirin may not outweigh the risks in some people at low risk of heart attack or stroke.

Remember, talk to your doctor or other health care provider to decide whether taking daily aspirin to help prevent cardiovascular disease may be right for you. Only a health care provider who knows your medical history can help you decide if the benefits outweigh the risks for your individual situation.

This information is intended only for health care professionals in the United States and is provided only for informational purposes. This information is intended to provide an example of the risks and benefits of a particular medicine. This page does not provide medical advice regarding the use of low-dose aspirin. The FDA has determined that cardiovascular indications for aspirin require the supervision of a physician (or other practitioner licensed to prescribe medicines) to ensure safe use. Patients should consult with their doctors or prescribing health care professional when considering using aspirin for cardiovascular indications.


> Next:  Strategies for Evolving Risks
< Previous:  Visualizing Risk with Aspirin

Medicine Safety Education Home

2390750590001
 
Monitoring Evolving Risks

Strategies for Monitoring and Communicating Evolving Risks

A medicine is approved for use in appropriate patients only when extensive testing shows that its benefits outweigh the risks for its intended use in those patients. But, sometimes, safety issues may arise even after a medicine is approved as it is used by more people with more varied backgrounds than those involved in clinical studies.

Pharmaceutical companies have extensive safety monitoring systems to help detect these issues. And when safety issues do arise, the companies work with regulatory agencies to determine the best course of action. This may include updating the product labeling and issuing safety alerts and other communications.

  • Learn more about product labeling
  • Learn more about medicine safety communications


> Next:  Medicine Safety Survey
< Previous:  Aspirin's Benefit-Risk Balance

Medicine Safety Education Home

2390746956001

You’ve seen headlines about medicines for which serious safety concerns developed, resulting in warnings to patients and doctors—and sometimes even the withdrawal of a drug from the market by the manufacturer.

After a new medicine is approved for use by a regulatory agency such as the U.S. Food and Drug Administration or the European Medicines Agency, safety issues may arise as the medicine is used by larger numbers and a wider variety of people than those involved in pre-approval clinical trials.

Pharmaceutical companies have extensive safety monitoring systems to help detect these issues. And when safety issues do arise, pharmaceutical companies work with regulatory agencies to determine the best course of action.

Now that you’ve learned about risk perception, take our survey to learn more about the factors that regulators may consider when making a decision about the risks of medicines—and find out how your own decisions compare to those of others. Click Next to take the survey.

Medicine Safety Survey

In a U.S. survey on medicine risk perception, the scenario below was presented to a research panel of 2,000 people representative of the general U.S. population. Read the scenario. Then, take the survey to see how your responses compare with theirs.

Scenario
Imagine that a new prescription drug for treating a serious disease becomes available in this country. Other drugs are also available for treating this disease. A study reveals that some people may have died from taking this new drug.

What do you think the government should do in this case?

Leave the drug on the market

Leave the drug on the market, but warn doctors and patients

Take the drug off the market

Not sure

Source: Slovic P, Peters E, Grana J, Berger S, Dieck GS. Risk perception of prescription drugs: results of a national survey. Drug Information J. 2007;41:81-100.


> Next:  Medicine Safety Timeline
< Previous:  Monitoring and Communicating Evolving Risks

Medicine Safety Education Home

2390963106001

This interactive survey is based on a U.S. survey on medicine risk perception that was presented to a research panel of 2,000 people representing the general U.S. population. Read the scenario to the left and then take the survey to see how your responses compare with theirs.

When you’ve completed the survey, click Next to find out more about how individuals and organizations work to ensure medicine safety from the first stages of testing and development to the ongoing monitoring of medicines in the general population.

Medicine Safety Survey

After survey respondents evaluated the initial scenario, the following cumulative results were recorded:


  • 0.4%
  • Leave the drug on the market
  • 33.7%
  • Leave the drug on the market, but warn doctors and patients
  • 54.0%
  • Take the drug off the market
  • 11.7%
  • Not sure


Survey respondents then considered some other circumstances. See how their opinions changed when the following factors were introduced:

The government and the drug's manufacturer are very actively gathering more information about the problem



You've taken the drug for many months and are very satisfied with it



The drug has been used safely and effectively for many years in another country



The risk of death or serious side effects turns out to affect only certain types of patients—elderly people who already have a liver problem, for example



The drug is more effective for most patients than other similar drugs on the market



Overall, the drug has fewer side effects for most patients than other similar drugs on the market

3.8% Leave the drug on the market

54.7% Leave the drug on the market, but warn doctors and patients

32.5% Take the drug off the market

8.6% Not sure

Like you, regulators weigh many factors when they make decisions or recommendations about giving the public access to certain medicines. This complex and ongoing regulatory oversight process is another example of balancing benefits and risks based on information as it becomes available.

8.5% Leave the drug on the market

58.8% Leave the drug on the market, but warn doctors and patients

22.9% Take the drug off the market

9.6% Not sure

Like you, regulators weigh many factors when they make decisions or recommendations about giving the public access to certain medicines. This complex and ongoing regulatory oversight process is another example of balancing benefits and risks based on information as it becomes available.

8.0% Leave the drug on the market

65.0% Leave the drug on the market, but warn doctors and patients

18.0% Take the drug off the market

8.6% Not sure

Like you, regulators weigh many factors when they make decisions or recommendations about giving the public access to certain medicines. This complex and ongoing regulatory oversight process is another example of balancing benefits and risks based on information as it becomes available.

4.8% Leave the drug on the market

73.0% Leave the drug on the market, but warn doctors and patients

17.8% Take the drug off the market

4.4% Not sure

Like you, regulators weigh many factors when they make decisions or recommendations about giving the public access to certain medicines. This complex and ongoing regulatory oversight process is another example of balancing benefits and risks based on information as it becomes available.

5.7% Leave the drug on the market

70.9% Leave the drug on the market, but warn doctors and patients

16.7% Take the drug off the market

6.6% Not sure

Like you, regulators weigh many factors when they make decisions or recommendations about giving the public access to certain medicines. This complex and ongoing regulatory oversight process is another example of balancing benefits and risks based on information as it becomes available.

7.7% Leave the drug on the market

71.9% Leave the drug on the market, but warn doctors and patients

13.8% Take the drug off the market

6.6% Not sure

Like you, regulators weigh many factors when they make decisions or recommendations about giving the public access to certain medicines. This complex and ongoing regulatory oversight process is another example of balancing benefits and risks based on information as it becomes available.

Source: Slovic P, Peters E, Grana J, Berger S, Dieck GS. Risk perception of prescription drugs: results of a national survey. Drug Information J. 2007;41:81-100.


> Next:  Medicine Safety Timeline
< Previous:  Monitoring and Communicating Evolving Risks

Medicine Safety Education Home

2390750595001
 
Patient Health Literacy

Patient Health Literacy

Patient health literacy can sometimes be a barrier in understanding medicine risk. Studies show that people from all ages, races, income, and education levels are challenged by this problem.


Click here to access AMA Foundation resources created to raise awareness and address the challenge of patient health literacy as an issue that affects medical diagnosis, treatment, and patient safety.


Medicine Safety Education Home

2390750590001
 

 

Navigator (click to expand and view section topics)(click to close)
  • Medicine Safety Timeline
  • Timeline: Drug Development Overview
  • Timeline: Safety in Drug Development View
  • Timeline: Safety Reports & Submissions
  • Timeline: Safeguards for Study Participants
  • Timeline: The Need for Post-Approval Safety Monitoring
  • Timeline: Safeguards for Patients Post-Approval
  • The Safety Journey
  • Case Studies
  • Case Study 1
  • Case Study 2
  • Case Study 3
  • Process Overview
  • Receiving a Safety Report
  • Capturing & Reviewing Information
  • Analyzing the Facts
  • Reporting & Communicating Risk

Medicine Safety Timeline

Medicine safety: An ongoing process

Patient safety is a paramount concern throughout the life of a medicine—and pharmaceutical companies have ethical and regulatory responsibilities to monitor the safety of the medicines they sell for as long as they are used by patients anywhere in the world.

Explore this section to view how safety is integrated into every phase of testing and development, and how efforts to manage potential safety issues in approved medicines continue for many years.

An important note for patients

Please note that all are welcome to explore the medicine safety timeline. However, this section is intended primarily for health care professionals.

> Next: Timeline: Drug Development Overview

Medicine Safety Education Home

2390750589001

The goal of safety reporting activities is to provide patients, health care professionals, and regulators with relevant information about the benefits and risks of medicines, so that they can make informed decisions about their use.

This section gives a “real-world” perspective of the processes and systems that pharmaceutical companies use to ensure that their safety reporting obligations are met, before and after regulatory approval.

Click on the Case Studies link to explore 3 hypothetical stories of patients who experience a particular type of event. Then follow the journey those individual case reports take.

Each case will be presented as a series of stops on a journey, as a pharmaceutical company:

 

  • Receives a report
  • Captures information about the case
  • Reviews and analyzes the facts about the individual case or about a series of cases
  • And reports out the data and takes action to communicate any change in risk

 

If you’d like to learn more about each step in the safety journey, click on the Process Overview link.

Timeline: Drug Development Overview

Roll over the timeline phases below for a brief description.

  • 1-6 Years
  • 5-7 Years
  • 1/2 - 2 Years
  • Ongoing
  • Discovery / Preclinical
  • Pre-Approval Studies

    Phase 1 Phase 2 Phase 3

  • Approval Process
  • Postapproval
  • First in-human decision

Drug Development

Developing a medicine that is effective in treating or preventing a specific disease with an acceptably low risk of side effects is a major project that can take up to 15 years. Only about 250 of every 10,000 compounds that enter the research and development pipeline will make it into human testing—and only 1 of those original 10,000 will actually become an approved medicine. Roll over each phase to learn more.

> Next:  Timeline: Safety in Drug Development
< Previous:  Medicine Safety Timeline

Medicine Safety Education Home

2390746958001
 
Close

Safety in Drug Development View >
Discovery/Preclinical

  • Preliminary Safety
    Testing
  • Preclinical Studies of
    "Lead" Compounds
  • Nonclinical
    Studies
 
Close

Safety in Drug Development View >
First in-human decision

Before testing of a potential medicine can proceed in humans, companies must provide documentation showing that there is no preclinical evidence that the medicine poses significant risk to humans. This documentation is reviewed by regulatory agencies to ensure that study participants will not face an unreasonable risk.

An example is the U.S. Investigational New Drug (IND) application filed with the FDA. The IND contains:

  • All the data and information related to the preclinical pharmacology and toxicology studies
  • A description of the manufacturing processes that will be used to create the study medicine
  • Descriptions of the clinical protocols that will be followed in the initial clinical studies
  • Information about the investigators who will oversee the administration of the medicine in these studies

In Europe, a Clinical Trial Application (CTA) must be filed before studies in humans can begin. The content is similar to that of the IND application, with an emphasis on identifying factors of risk to clinical study participants and applying risk mitigation strategies to study design.

Once clinical studies are underway, numerous safeguards are in place to protect the rights and safety of patients participating in clinical trials. To learn more, choose the "Safeguards for Study Participants" view of the timeline.

Close

Safety in Drug Development View >
Phase 1

  • Identifying Inappropriate
    Compounds
  • Phase 1
    Testing
 
Close

Safety in Drug Development View >
Phase 2

Principal goal: Get a clear understanding of how the study medicine performs in terms of both its efficacy in treating the disease under study and its safety in the intended patient population.

Participants: Because this is usually the first time the study medicine will be used in patients—rather than in healthy volunteers—researchers are cautious. Phase 2 trials may be conducted in hospitalized patients so they can be more closely monitored. In addition, more than one Phase 2 study may be performed. Phase 2 studies include a relatively small number of patients—usually only about 50 to 500. While 500 people may seem like a lot, it is far too small a number to detect uncommon or rare adverse events that occur in only 1 person in 1,000—or 1 in 10,000 or 100,000.

What researchers look for: Researchers use the data from Phase 2 studies to further refine the optimal dose strength and dosing schedule of the study medicine.

Close

Safety in Drug Development View >
Phase 3

If the safety and early efficacy data from Phase 2 suggest a favorable benefit-risk profile, Phase 3 studies of the medicine may begin.

Participants: These are usually larger (about 1,000 to 5,000 patients) and of longer duration than the earlier studies.

Principal goal: Generate a more complete picture of the safety and efficacy of the study medicine. The data from these studies are used to determine the appropriate use of the medicine, its therapeutic benefit and known side effects, and potential interactions with other medicines. All of this will be communicated through the product labeling.

Study design: These are generally well-controlled studies designed in such a way that they can be considered as pivotal studies by regulatory agencies.

For a study to be considered pivotal, it usually must:

  • Have a randomized design
  • Be large enough in size to produce a statistically significant demonstration of efficacy and meaningful information about the safety and the benefit-risk profile of the medicine
  • Have a control arm in which patients receive either a placebo or currently accepted standard therapy
  • Usually use double-blinded treatments—i.e., blinded so neither the physician nor the patient is aware of whether they are being treated with the study medicine, the placebo or standard therapy, or both. (There are situations, however, where open-label Phase 3 studies are considered pivotal. This is particularly true in oncology studies.)

Note that as long as the study is ongoing, all involved—including the pharmaceutical company—are usually blinded as well. The investigator may unblind an individual patient's study medicine for emergency medical reasons. The Data Safety Monitoring Board (DSMB)/Data Monitoring Committee (DMC) may also require access to unblinded information. It is only after a study is completed that the company unblinds the entire dataset so it can be adequately analyzed and the results reported.

Phase 3 studies can involve hundreds of sites around the world to help ensure that the medicine is investigated in a large and diverse patient population. The coordination needed to conduct the study at all of those sites and to collect—and then analyze—the data generated is a massive undertaking that can take several years. An appropriate level of safety and efficacy must be demonstrated, usually in multiple pivotal studies, for the medicine to gain regulatory approval for use in the general population. Additional Phase 3 studies may be conducted to obtain more information about the medicine being studied.

Close

Safety in Drug Development View >
Approval Process

  • Medicine Approval
     
  • Label Approval
     
 
Close

Safety in Drug Development View >
Post-Approval

Regulatory approval is by no means the final safety checkpoint for a new medicine. Rather, it represents an initial threshold indicating that the proven benefits of a medicine for the intended population and use outweigh its known risks at the time of approval. Safety surveillance continues for as long as the medicine is prescribed because even the rigorous pre-approval testing cannot detect every possible side effect.

In fact, it is expected by regulatory agencies, by the pharmaceutical company sponsoring the new medicine, and by the doctors who prescribe it that additional safety risks or information may become apparent as the newly approved medicine is used:

  • More widely—in much larger numbers and broader groups of patients
  • For longer periods of time—for months or years
  • Under "real-world" circumstances rather than the more predictable and closely monitored conditions of clinical trials

To learn more about the ongoing commitment to safety monitoring of approved medicines, select the "Safeguards for Patients Post-Approval" view of the timeline.

Timeline: Safety in Drug Development

Roll over and click the timeline below for information.

  • 1-6 Years
  • 5-7 Years
  • 1/2 - 2 Years
  • Ongoing
  • Discovery / Preclinical
  • Pre-Approval Studies

    Phase 1 Phase 2 Phase 3

  • Approval Process
  • Postapproval
  • First in-human decision

Safety in Drug Development

During the research and development process, medicines are evaluated for safety continuously against the rigorous standards expected by the scientific and medical communities, government and other health agencies, and the pharmaceutical companies themselves. The more common side effects of a medicine are identified during the research and development process. However, rare side effects can sometimes only be identified when the medicine has been taken by many thousands of patients in the general community.

After approval of a medicine, the safety evaluation continues so that new information coming from use of the medicine in the general population can be identified and, when necessary, acted upon as quickly as possible. Explore the timeline to learn more about medicine safety at each stage of development.

> Next:  Timeline: Safety Reports & Submissions
< Previous:  Timeline: Drug Development Overview

Medicine Safety Education Home

2390746958001
 
Close

Safety Reports & Submissions >
Pre-approval Studies

  • Expedited
    Reports
  • Clinical Study
    Reports
  • IND Annual
    Reports
  • Annual Safety
    Reports
  • Risk
    Management
 
Close

Safety Reports & Submissions >
Approval Process

  • Proposed
    Labeling
  • Risk Management
    Plans
  • Common Technical
    Document (CTD)
 
Close

Safety Reports & Submissions >
Post-Approval

  • Reporting
    Frequencies
  • 15-Day
    Reports
  • Cumulative Safety
    Reports
  • NDA
    Reports
  • Managing
    Risk
 

Timeline: Safety Reports & Submissions

Roll over and click the timeline below for information.

  • 1-6 Years
  • 5-7 Years
  • 1/2 - 2 Years
  • Ongoing
  • Discovery/Preclinical
  • Pre-Approval Studies
  • Approval Process
  • Postapproval
  • First in-human decision

During the research and development process—and after a medicine is approved—pharmaceutical companies have ethical and regulatory responsibilities to collect, analyze, and communicate information about the benefit-risk profiles of their products. In order to ensure that companies meet these obligations, regulatory agencies require them to submit many different types of reports and documents during the lifetime of a medicine. For an overview of these documentation requirements, roll over the stages of the timeline—or click on the phases to learn more.

> Next:  Timeline: Safeguards for Study Participants
< Previous:  Timeline: Safety in Drug Development View

Medicine Safety Education Home

2390746958001
 
Close

Safeguards for Study Participants >
Pre-approval Studies

  • Ethics
    Committees
  • Adverse Event
    Reporting
  • Data
    Monitoring
  • Regulatory
    Oversight
  • Risk
    Management
 

Timeline: Safeguards for Study Participants

Roll over and click the timeline below for information.

  • 1-6 Years
  • 5-7 Years
  • 1/2 - 2 Years
  • Ongoing
  • Discovery/Preclinical
  • Pre-Approval Studies
  • Approval Process
  • Postapproval
  • First in-human decision

Safety is built into the process

The first clinical studies in humans are conducted to test safety in small numbers of subjects who are usually (but not always) healthy volunteers—that is, individuals who do not have the disease for which the medication is being developed. In these early studies, information is also obtained to help design the safest and most appropriate dosing in later clinical trials. As the process continues, a larger number of subjects—patients with the condition or disease to be treated—are recruited.

Throughout this rigorous testing process, multiple safeguards are in place to protect the rights and safety of study participants. Click on the Pre-Approval Studies section of the timeline to learn more.

> Next:  Timeline: The Need for Post-Approval Safety Monitoring
< Previous:  Timeline: Safety Reports & Submissions

Medicine Safety Education Home

2390746958001
 
Close

Post-Approval Safety Monitoring >
Post-Approval

  • Number of
    Patients
  • More Diverse
    Patient Population
  • Longer Time
    Periods
  • Uncontrolled
    Conditions
 

Timeline: The Need for Post-Approval Safety Monitoring

Roll over and click the timeline below for information.

  • 1-6 Years
  • 5-7 Years
  • 1/2 - 2 Years
  • Ongoing
  • Discovery/Preclinical
  •  
  • Approval Process
  • Post-Approval
  • First in-human decision

Why aren't all medicine safety issues identified before approval?

Although it represents a significant judgment about the safety and efficacy of a new medicine, receiving regulatory approval is not the final safety checkpoint. Rather, it is an important threshold based on sufficient clinical data to show that the benefits of a medicine for the intended population and use outweigh its known risks at the time of approval.

Safety surveillance continues for as long as the medicine is prescribed. This is because the rigorous clinical testing that medicines undergo before approval cannot detect every possible side effect. In fact, it is recognized by regulatory agencies, by the pharmaceutical company sponsoring the new medicine, and by the doctors who prescribe it that additional safety risks may become apparent as the newly approved medicine is used:

  • More widely—in much larger numbers and broader groups of patients
  • For longer periods of time—sometimes for months or years
  • Under "real-world" circumstances rather than the more predictable and closely monitored conditions of clinical trials

Click on the Post-Approval section of the timeline to learn about the significant differences between clinical studies and real-world conditions of use.

> Next:  Timeline: Safeguards for Patients Post-Approval
< Previous:  Timeline: Safeguards for Study Participants

Medicine Safety Education Home

2390746958001
 
Close

Safeguards for Patients Post-Approval >
Post-Approval

  • Safety
    Signals
  • Identifying
    Signals
  • Post-approval
    Safety Studies
  • Evaluating and
    Managing Risk
  • Communicating
    Risk
 

Timeline: Safeguards for Patients
Post-Approval

Roll over and click the timeline below for information.

  • 1-6 Years
  • 5-7 Years
  • 1/2 - 2 Years
  • Ongoing
  • Discovery/Preclinical
  •  
  • Approval Process
  • Post-Approval
  • First in-human decision

Why is post-approval pharmacovigilance important?

Some might argue that longer pre-approval clinical studies should be conducted in greater numbers of subjects, from more varied populations. However, a pharmaceutical company could study three times the number of patients normally studied in a clinical development program—and follow these patients for three times the length of a typical study—and there would still be insufficient numbers of patients to identify certain rarely occurring adverse events and insufficient time to identify events with long latency periods. It would take even longer to get useful medicines into the hands of the patients in whom the therapeutic benefits outweigh potential risks, and many rare or delayed events could still go undetected.

Instead, pharmaceutical companies and regulatory agencies recognize that it is not possible to identify all risks during pre-approval clinical studies, no matter how large or how long. Therefore, they take steps post-approval to monitor emerging safety issues and manage known risks. This set of strategies is collectively known as pharmacovigilance.

Click on the Post-Approval section of the timeline to learn more about the proactive systems pharmaceutical companies use to detect, assess, and understand new safety issues or new aspects of already identified safety risks.

How is this information used to help patients?

Rarely does the risk information discovered post-approval alter the benefit-risk relationship so dramatically that a medicine is withdrawn or its use severely restricted. However, when this occurs, it usually receives considerable public attention. The more common—but less dramatic—scenario is that newly identified safety issues help the pharmaceutical companies, working with regulatory agencies, to better understand who should or should not take the medicine or how to update dosing recommendations. This information is then disseminated to health care professionals—and, through them, to patients—using a variety of means.

> Next:  The Safety Journey
< Previous:  Timeline: The Need for Post Approval Safety Monitoring

Medicine Safety Education Home

2390746958001
 
The Safety Journey

The Safety Journey

The goal of safety reporting activities is to ensure that patients, health care professionals, and regulators have all the relevant information about the benefits and risks of medicines to help them make informed decisions about their use.

Get a "real-world" perspective of the processes and systems that pharmaceutical companies have in place to ensure that their safety reporting obligations are met—both pre- and post-approval.

Explore how a company:

  • Learns of an event
  • Captures information about the case
  • Reviews and analyzes the facts about the individual case or about a series of cases
  • Reports out the data and takes action to communicate change in risk

To learn more about each step in the safety journey, visit the Process Overview section.

> Next:  Case Studies
< Previous:  Medicine Safety Timeline

Medicine Safety Education Home

2390750595001
 

The Safety Journey: Case Studies

Click on the hypothetical case studies below to follow the journey of patients who experience a particular type of event as they provide safety information about the medicine that benefits other patients and their physicians.

  •  
  •  
  •  
  • Case Study 1

    A pre-approval clinical study investigator reports a serious unexpected adverse event.

  • Case Study 2

    A nurse practitioner mentions a patient's car accident while conversing with a company representative.

  • Case Study 3

    A patient calls a helpline because she received the wrong type of medication pack.


> Next:  Case Study 1
< Previous:  The Safety Journey

Medicine Safety Education Home

2390746958001
 

Case Study 1: A pre-approval clinical study investigator reports a serious unexpected event.

2390746961001
 
 

To view this interactive feature, you must have Flash 9 installed on your computer.
If you do not have Flash 9, you can download it from the Adobe web site.

Receiving a safety report

Narrator: A patient in a pre-approval clinical study suffers a serious skin reaction, and the clinical investigator completes a serious adverse event report form within hours of becoming aware of the skin reaction.

A study coordinator faxes the form to the dedicated clinical study safety unit of the sponsoring pharmaceutical company. Within hours of receipt, the form is reviewed and prioritized by a trained professional to ascertain whether it meets expedited reporting criteria.

Capturing information

The patient's condition suggests Stevens-Johnson syndrome—a potentially life-threatening, serious adverse event. The investigator believes that there is a reasonable possibility that it was caused by the study medicine and therefore classifies it as "causally related" to the medicine.

With these criteria, the case will be given the highest priority because it may meet expedited reporting criteria. While information is being entered into the company's safety database, a company physician—who is an expert in both the study medicine suspected of causing the reaction and the diseases being studied in the protocol—is alerted.

Reviewing and analyzing the facts

The company physician agrees with the investigator's assessment that, although the patient was seriously ill and receiving multiple medications at the time, there is a reasonable possibility that the study medicine contributed to the development of—or directly caused—the event. Either the investigator or company physician's assessments of causality will trigger reporting of the event to regulators.

In addition, the event is classified as "unexpected" because it is not mentioned in the Investigator Brochure. This is a key document provided to all study investigators, which lists all that is known to date about the medicine's safety profile.

The episode of Stevens-Johnson syndrome is a "Suspected Unexpected Serious Adverse Reaction" (SUSAR) and meets the criteria for expedited reporting. Since the event is also life-threatening, it must be reported out to the FDA and many other worldwide regulatory agencies within 7 days of the company's first awareness.

Reporting events and communicating risks

Within 7 days of the initial fax being received by the pharmaceutical company, a "7-day report" of the case is sent to the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and regulatory agencies in other countries where the medicine is under study. This will be followed by a follow-up report with additional significant information about the case, including the patient's outcome (e.g., whether or not she is recovering).

In addition, a letter must be sent to all investigators on the study informing them of this previously undocumented potential serious risk. In some countries, the company will also send letters out to the Institutional Review Boards (IRBs) or Ethics Committees overseeing the study. In other countries, this is the responsibility of the investigator.

These independent committees will consider how this newly identified potential risk may impact the study participants, the objectives of the study, and how it should be communicated to patients. Once patients receive the information about such a new risk, they will be asked to renew their consent to continue participating in the study with a revised informed consent document.

Fast reaction times are essential

The well-being of clinical study participants is of paramount importance. This makes it crucial to respond to new information about the safety of a medicine as rapidly as possible. Should similar cases be reported in the future, informed decisions can quickly be made about the benefits and risks of discontinuing the medicine's development versus continuing with development and—if evidence warrants—eventually seeking regulatory approval.

An important part of the regulatory approval process will involve decisions on how to communicate safety risks in the medicine's labeling. In the U.S., for example, this might involve additions to the adverse events listed in the Adverse Reactions section of the Prescribing Information. In some cases, it may also require an update to the Warnings and Precautions sections or even the creation of a black box warning—the strongest warning that can be communicated for a medicine.

> Next:  Case Study 2
< Previous:  Case Studies Overview

Medicine Safety Education Home

2390746958001
 

Case Study 2: A nurse practitioner mentions a patient's car accident while conversing with a company representative.

2390963111001
 
 

To view this interactive feature, you must have Flash 9 installed on your computer.
If you do not have Flash 9, you can download it from the Adobe web site.

Receiving a safety report

Nurse Practitioner: A lot of my patients worry about the risk of side effects. And it's so important to put things in perspective for them. I had one patient who was really anxious about his risk for some of the more uncommon side effects with one of your medications. Now, he's in the hospital after a car accident.
Sales Representative: So this patient was taking our medicine and now he's in the hospital?
Nurse Practitioner: Yes.
Sales Representative: That's an adverse event, and I'm going to need to call it in to our safety group.

Capturing information

The sales representative has been trained to report this adverse event as soon as possible. She calls the information in to a colleague in the company's medicine safety department, who will contact the nurse practitioner for any additional information.

Because the patient is hospitalized, this is considered a serious adverse event. The case is given a high priority because it could require a 15-day reporting turnaround to regulatory agencies. The clock "started ticking" from the moment the nurse practitioner told the company representative about the event. The medicine safety department must act swiftly to contact a health care professional with direct knowledge of the case, to gather more information about the patient and the adverse event.

Reviewing and analyzing the facts

As information is gathered about the case, no evidence is found that the patient had experienced any other adverse events before the accident. The event is coded as "Accidental Injury," and it is considered unexpected because it is not listed in the product's label (for example, prescribing information). All spontaneously reported adverse events that are serious and unexpected must be reported to regulatory agencies within 15 days—regardless of the causality of the event. Therefore, the case is processed on an expedited basis.

Full details of the case are recorded in the pharmaceutical company's safety database. Rapid follow-up is conducted to obtain further details and learn about the patient's outcome so that the information about the case is as complete as possible.

Although the event is seemingly unrelated to the medicine, it has been permanently recorded in the company's safety database. This database provides a record of the cumulative safety experience with the medicine and will be routinely scrutinized to look for trends that need to be evaluated further. In the event that a side effect of the medicine (such as drowsiness or impaired judgment) did contribute to the accident, an excess of these events might be apparent in the database—and a safety signal would be observed.

Reporting events and communicating risk

After the initial 15-day expedited report has been sent to the regulatory agencies, further reports may be submitted if significant follow-up information is received about the case—such as the patient making a full recovery or suffering permanent disability. Or the company may learn of another condition unrelated to use of the medicine that might have contributed to the accident—a "mini-stroke" for example.

In addition, the case will be included in aggregate reports of safety data collected on the medicine. These are sent out to regulatory agencies at mandatory time intervals after the medicine has been approved.

All safety reports are important

This example demonstrates how companies have pharmacovigilance systems in place to maintain regulatory compliance with expedited reporting regulations. This ensures that they are able to identify and communicate any changes in a medicine's benefit-risk profile as quickly as possible. This example also illustrates that all adverse event reports are taken very seriously, irrespective of the likelihood that they were caused by the medicine. By following the same standardized procedures for all reports received, the chances of detecting a safety signal are improved.

  • Learn more about safety signals.

> Next:  Case Study 3
< Previous:  Case Studies Overview

Medicine Safety Education Home

2390746958001
 

Case Study 3: A patient calls a helpline because she received the wrong type of medication pack.

2390750594001
 
 

To view this interactive feature, you must have Flash 9 installed on your computer.
If you do not have Flash 9, you can download it from the Adobe web site.

Receiving a safety report

Operator: Patient Support Line. How may I help you today?
Patient: Well, I just got back from the pharmacy and opened my medication pack, and it doesn't look anything like my doctor explained that it would.
Operator: In what way?
Patient: Well, the pills I received are all the same color, but my doctor said that there'd be different strength pills—each with a special color—so I could start off gradually. I didn't take any yet because I was concerned that something was wrong.
Operator: It sounds like you may have received the wrong pack. Let me get a few more details...

Capturing and reviewing information

Even before this medicine was approved, the potential for dosing or medication errors was recognized because patients had to increase their dose gradually over time. Therefore, the manufacturer developed a Risk Management Plan while the drug was still undergoing clinical testing. The plan included:

  • Special packaging
  • Educational programs for health care professionals
  • A telephone helpline to support patients, staffed by medical professionals specially trained to recognize and report adverse events and medication errors

In this case, after collecting some basic information about the report, the helpline professional transmits the data to the company's medicine safety department. In addition, the patient is advised to return to the pharmacy to ensure that the correct medication and dosing instructions are received.

Reviewing and analyzing the facts

This report will be reviewed, and letters requesting further information will be sent out to the patient reporting the event. With the patient's permission, information will also be requested from health care professionals with knowledge of the case. The information received in response to these follow-up requests will also be entered into the safety database and further assessed to provide a more complete picture of the circumstances surrounding the event.

The event will be coded as "wrong drug strength dispensed" to aid retrieval of this and similar cases from the database for review in the future. This consistent approach will enable the safety group responsible for the product to monitor the frequency of medication errors and assess the effectiveness of the Risk Management Plan.

Reporting events and communicating risk

If a consistent pattern of medication errors emerges, the company may need to revise its risk management approach—including its product packaging and educational strategies. Companies routinely report to regulatory agencies on the outcomes of a Risk Management Plan and discuss proposals for modifications that will improve risk management in the future.

A change to the product labeling may also be deemed necessary. Companies often will meet with regulatory agencies to discuss labeling revisions that may be required for the following types of documents:

  • Physicians' Prescribing Information (U.S.)
  • Summary of Product Characteristics (Europe)
  • Patient Information Leaflet or Medication Guide

Learning and improving

This example helps to illustrate the breadth of safety information that is collected. Even though no adverse event occurred, the patient was "at risk" of an event had she taken the incorrect dose of medicine. Accordingly, medication errors should be reported so they can be reviewed, and the need for further actions to reduce risk can be assessed.

> Next:  Process Overview
< Previous:  Case Studies Overview

Medicine Safety Education Home

2390746958001
 

The Safety Journey: A theoretical process overview

Explore this section to learn more about each step in the reporting, analysis, and communication of medicine safety risks. Click "Receiving a Safety Report" to begin the step-by-step overview.

> Next:  Receiving a Safety Report
< Previous:  Case Study 3

Medicine Safety Education Home

2390746958001
 

The Safety Journey: A theoretical process overview

Step 1: Receiving a safety report

Adverse event reports come to a pharmaceutical company from many different sources. Reports may come from clinical studies (also called clinical trials) or from noninterventional studies such as patient support programs or observational studies.

Pharmaceutical companies may also receive spontaneous reports from a variety of sources, including:

  • Health care professionals
  • Patients
  • Caregivers
  • Lawyers
  • Regulatory agencies
  • Medical/scientific literature, including individual case reports
  • Media

Regardless of the source of the report, the regulatory timeline for submitting expedited reports begins the moment the first person anywhere in the company learns of the event. So anyone who works for, or on the behalf of, the company who is likely to receive this type of information must be trained to recognize reports of adverse events and forward them to the company's medicine safety department.

> Next:  Capturing & Reviewing Information
< Previous:  Process Overview

Medicine Safety Education Home

2390746958001
 

The Safety Journey: A theoretical process overview

Step 2: Capturing and reviewing information

After an adverse event report is received by a pharmaceutical company, all information about the case is entered into the company´s safety database. From here, the case will be reviewed by medical professionals and reported out to regulatory agencies.

In most companies, an initial prioritization step helps to ensure reports that may require expedited reporting are processed and reviewed as soon as possible. If expedited reporting criteria are met, the case must be reported to regulators—and sometimes to study investigators—within a mandatory 7 or 15 days of the company first learning of the event, depending on certain factors and local regulatory requirements.

During case review, additional information may be requested for expedited cases to provide a more complete picture of the event and its surrounding circumstances. Responses to these requests—together with any other information received subsequent to the initial report—are known as "follow-up information." This additional information is also entered into the safety database and reviewed to evaluate whether it needs to be reported.

The pharmaceutical industry professionals who review and assess case data and follow-up information—physicians, other health care professionals, and scientists—are all highly trained in medicine safety. Their work is governed by detailed standard operating procedures developed by each company to ensure compliance with regulatory reporting requirements and other applicable laws. These procedures—and the training that accompanies them—are reviewed frequently during regulatory inspections.

During data entry, any adverse events and medicines involved in the case are coded using standardized dictionaries such as the Medical Dictionary for Regulatory Activities (MedDRA) or the World Health Organization (WHO) Drug dictionary. This uniformity not only aids in the assessment of an individual case; it is also critically important in compiling aggregate reports of adverse event data and successfully detecting safety signals from multiple cases through procedures like data mining.

> Next:  Analyzing the Facts
< Previous:  Receiving a Safety Report

Medicine Safety Education Home

2390746958001
 

The Safety Journey: A theoretical process overview

Step 3: Analyzing the facts

In most companies, serious adverse event reports are analyzed by medical reviewers. These professionals are usually physicians, who use their practical clinical experience to assess how the adverse events reported for a medicine affect the benefit-risk profile of the product. This medical opinion will be included when reports are submitted to regulatory agencies and will be considered when decisions are made about possible changes to the medicine's label (for example, professional prescribing information and information for patients).

For clinical study cases, the medical reviewer is also responsible for evaluating the possible causes of an individual adverse event. This "causality assessment" can be particularly challenging in cases where a patient with multiple concurrent illnesses is receiving a number of concomitant medications.

The medical reviewer also checks that the information in each report is correct from a clinical and regulatory standpoint. This helps ensure that the safety experts who review the reports both within the company and in regulatory agencies worldwide have as complete a presentation of the patient's data and clinical course as possible.

Once the information for a report is considered complete and has been entered in the safety database, it is permanently available for future analysis of safety trends for that medicine. The data may be reviewed cumulatively and in an aggregate fashion, both manually or through automated data mining techniques.

  • Learn more about data mining

> Next:  Reporting & Communicating Risk
< Previous:  Capturing & Reviewing Information

Medicine Safety Education Home

2390746958001
 

The Safety Journey: A theoretical process overview

Step 4: Reporting and communicating risk

Individual case reports are submitted to regulatory agencies when they meet expedited reporting criteria. In addition, all cases in the safety database will be incorporated into periodic reports—designed to report safety information about a medicine that accumulates over time. These reports are sent to regulatory agencies at regular time intervals determined by the length of time for which the medicine has been approved.

The reporting of adverse event data to regulatory agencies is undergoing a transition from paper-based reporting like the FDA's MedWatch forms (or CIOMS* forms in many other countries) to electronic reporting. This reporting method uses a standardized format that specifies the structure of the data elements and technical aspects of the data transmission and enables near-simultaneous transmission to multiple agencies.

In addition to distributing reports to regulatory agencies, pharmaceutical companies also communicate changes in risk information, when warranted, to investigators, physicians, and patients through vehicles such as investigator letters or "Dear Health Care Professional" letters, labeling changes, and other targeted medical communications.

*CIOMS=Council for International Organizations of Medical Sciences.

> Next:  Partnering to Protect Patients
< Previous:  Analyzing the Facts

Medicine Safety Education Home

2390746958001
 

 

Navigator (click to expand and view section topics)(click to close)
  • Regulatory Agencies & the Pharmaceutical Industry
  • Industry & Patients
  • Industry & Health Care Professionals
  • Regulatory Agencies & Patients
  • Regulatory Agencies
    & Health Care Professionals
  • Health Care Professionals & Patients

Partnering to Protect Patients

All medicines have benefits and risks—and individual patients react to medicines differently. That is why patients must work with their doctors to carefully weigh the benefits of a medicine against its risks for their individual situation—and make the choice that's right for them.

To help protect patients, an extensive network is in place to identify and manage possible safety concerns associated with the medicines they take.

Click on the connection between any two of the images below to see how that partnership works as part of the larger network.

To view this interactive feature, you must have Flash 9 installed on your computer.
If you do not have Flash 9, you can download it from the Adobe web site.

An important note for patients

Please note that all are welcome to explore this section. However, some of the information provided is intended primarily for health care professionals.

Next: > Regulatory Agencies & the Pharmaceutical Industry

Medicine Safety Education Home

2390746960001

All medicines have benefits and risks, and the safety of a medicine must be carefully considered for each individual.

Different patients react to medicines differently; a life-saving medicine that bears potential side effects for one patient may be perfectly safe for another. That is why patients, in consultation with their doctors, must assess the benefit-risk balance of a medicine and make the choice that’s right for them.

For patients who take medicines, an extensive network is in place to identify and manage possible safety concerns—and patients themselves are part of this network.

Click on any two of the images to the left to see how patients, health care professionals, pharmaceutical companies, and regulatory agencies all work together to make taking medicines as safe as possible.

If you are a patient, please note that all are welcome to explore this section. However, some of the information provided here is intended primarily for doctors, nurses, pharmacists, and other health experts.

Regulatory Agencies & Industry

Partnering to Protect Patients:
Regulatory Agencies &
the Pharmaceutical Industry

Pharmaceutical companies and regulatory agencies work together to enhance patient safety when a medicine is first being studied (pre-approval) and after it becomes available to patients and their health care providers as a treatment option, following authorization by regulatory agencies (post-approval).

Learn more about regulatory agencies worldwide

Regulatory agencies are government or nongovernment authorities, responsible for oversight of the effectiveness, safety, manufacture, and distribution of medicines in a specific country or region of the world such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).

  • Read about regulatory agencies in different regions of the world

Pre-approval

Pharmaceutical companies and regulatory agencies communicate frequently to identify risks of a medicine at each step in the testing and approval process.

Before testing of a medicine begins in humans

Before a potential new medicine can be tested in humans, pharmaceutical companies prepare comprehensive submissions for review by regulatory agencies, presenting all findings from laboratory and animal studies. These are known as:

  • The Investigational New Drug (IND) submission in the U.S.
  • The Clinical Trial Application (CTA) in Europe

The intent is to demonstrate an understanding of the medicine's mode of action and the level of potential significant risk to humans, and to provide plans for studying the medicine in humans based on this information.

These submissions are carefully reviewed by highly—trained government scientists, whose most important consideration is the protection of clinical study subjects.

Back to top

 

During the conduct of pre-approval clinical studies

Reports and analyses
Pharmaceutical companies and the investigators who help conduct clinical studies collect reports of adverse events experienced by study participants and regularly submit safety information to the FDA and other regulatory agencies. These submissions include:

  • Expedited reports—submitted to regulatory agencies within short timeframes. The specific requirements may vary by regulatory agency, but factors typically include the seriousness of the specific adverse event, whether it would be expected to occur, and whether it might be related to the investigational medicine.
  • Aggregate reports of safety—included in regulatory submissions such as Annual Safety Reports (ASRs) in Europe or IND Annual Reports in the U.S. They contain listings and tabular analyses of adverse events observed in clinical trials. They also include narrative sections alerting regulators to potential areas of concern that may require modification of the investigational plan or other efforts to enhance the protection of patients who have volunteered to participate in the clinical study.
  • Learn more about patient safety in clinical studies

Inspections and audits
Regulatory agencies perform inspections (both announced and unannounced) to monitor the procedures and processes in place for collecting, reviewing, analyzing, and reporting safety data. These inspections may take place while data is being collected or after the study is completed and may occur anywhere in the world—at the operations of the pharmaceutical companies that sponsor the studies or at individual study sites in hospitals or research centers.

Risk Management Plans (RMPs)
Based on the accumulating safety profile of the medicine, many pharmaceutical companies have routinely developed Risk Management Plans to protect the safety of clinical study participants as well as patients taking the medicine after it is approved by regulatory agencies for use outside of clinical studies. In Europe, RMPs are now required as a condition of approval of a medicine.

  • Learn more about Risk Management Plans

Risk Evaluation and Mitigation Strategy (REMS)

In the United States, the FDA may require a risk management framework called a Risk Evaluation and Mitigation Strategy (REMS) at the time of NDA approval, when necessary to ensure that the benefits of a medicine outweigh its risks. The FDA may also require a REMS post-approval, based on new safety information. Pharmaceutical companies may also voluntarily submit a REMS.

All REMS must include an assessment of the REMS minimally at 18 months, three years, and during the seventh year after approval of the REMS. The FDA may waive the requirement at year seven. A REMS may also include a Medication Guide or patient package insert, a communication plan to health care practitioners, and elements to assure safe use of the product. Failure to comply with an element of an approved REMS may subject a pharmaceutical company to civil penalties and other sanctions.

Back to top

 

After the completion of pre-approval clinical studies

Pharmaceutical companies undertake a comprehensive and detailed analysis of all the safety and effectiveness data collected and present it to regulatory authorities:

  • As part of the approval submission (for example, the New Drug Application [NDA] in the U.S. or the Marketing Authorization Application [MAA] in Europe), and
  • In formal review meetings conducted to determine whether the known benefits and risks of a medicine support approval or if additional analysis, testing, or safety data collection may be required.

Pharmaceutical companies also work with regulatory agencies to:

  • Develop appropriate content and wording of a medicines professional prescribing information, including the safety sections such as the U.S. Prescribing Information or the Summary of Product Characteristics in Europe, often referred to as "labels," and
  • Determine the content of consumer product information such as a patient-focused package insert in the U.S. or a Patient Information Leaflet in Europe

Back to top

 

Post-approval

After a medicine is approved, pharmaceutical companies and regulators continue to work together to help identify and manage risks through the following reports, requirements, and reviews.

Adverse event reports

Pharmaceutical companies continue to collect and analyze safety information after a medicine has been authorized for use. As long as a medicine is on the market, companies continue reporting adverse event data to regulatory agencies through:

  • Expedited reports: Certain important safety information is reported in an expedited manner (for example, within 15 days of awareness), based on country regulatory requirements, including whether the event is expected with the product and how serious the adverse event may be. Technological advances and international data standards now enable rapid and nearly simultaneous electronic transmission to multiple regulatory agencies to make the information available as quickly as possible. Medically trained evaluators then review these reports for impact on patient safety.
  • Periodic reports: Aggregate safety data from individual case safety reports are sent to regulatory agencies in regularly scheduled periodic reports. These reports may contain additional information such as data from post-approval safety studies or information solicited from health care professionals or patients. Examples of this type of report include the U.S. Periodic Adverse Drug Event Report (PADER), the Periodic Safety Update Report (PSUR), and the Early-Phase Pharmacovigilance report in Japan.
  • Learn more about Cumulative Safety Reports

Regulatory agencies review these reports for emerging safety concerns or potential lack of efficacy, and may rely on the data to take appropriate action to protect patients. In addition, scientists employed by regulatory agencies perform independent analyses of safety data. Like their counterparts in academia and industry, their innovative research into pharmacovigilance methods is recognized in peer-reviewed scientific journals and scientific discussion forums.

Regulatory agencies may also notify pharmaceutical companies of spontaneous adverse event reports they receive directly from noncompany sources through methods such as:

  • Regular reports in Europe
  • The FDA's MedWatch Partners Program in the U.S.

Back to top

 

Inspections and reporting requirements

Regulatory agencies perform inspections (often unannounced) of pharmaceutical company operations to monitor the procedures and processes in place for collecting, analyzing, and reporting safety data.

Pharmaceutical companies also report to regulatory agencies on interim and final outcomes of each component of their product-specific Risk Management Plans (RMPs). These plans may include post-approval studies to gather further safety information, such as adverse event data in patients with certain characteristics (e.g., specific demographics, organ dysfunction, underlying conditions, or concomitant medications).

Back to top

 

Ongoing safety activities

Regulatory agencies continue to review and monitor:

  • The summary document(s) that provide information for the safe and effective use of a medicine: As knowledge of a medicine's benefit-risk profile expands with further study and use, a pharmaceutical company may meet with regulatory agencies to discuss interpretation of data. This may lead to agreements for future studies or modifications of the product's labeling—which refers to the prescribing information for health care professionals and may include patient information leaflets.
  • Approval status: In extreme instances, companies and regulators may participate in formal hearings to determine whether to continue, modify, or withdraw approval.
  • How the uses, benefits, and risks of medicines are portrayed to health care professionals and patients: Regulatory agencies monitor and frequently work with pharmaceutical companies to ensure that information is presented with fair balance in promotional materials to health care professionals as well as in direct-to-consumer advertising (DTC). In the U.S., a division of the FDA is dedicated to ensuring that appropriate claims regarding indications and use—as well as a fair balance of the benefits and risks of a product—are presented clearly to health care professionals and patients in all communications.

Back to top

> Next:  Industry & Patients
< Previous:  Partnering to Protect Patients

Medicine Safety Education Home

2390963112001
 
Pharmaceutical Industry & Patients

Partnering to Protect Patients: The Pharmaceutical Industry & Patients

Pharmaceutical companies work to provide information to—and obtain information from—the patients who take the medicines they develop through the following forms of ongoing communication:

 

Patient information leaflets (or medication guides, where applicable)

These nontechnical materials are designed to complement information provided to patients by their health care providers. They typically include safety information such as:

  • Most common adverse events
  • Relevant safety warnings and precautions
  • How the effect of the medicine may be altered by other substances a patient is taking (such as other medicines, herbal products, and certain foods or beverages)

Patient-driven communications

Patients may contact pharmaceutical companies directly to ask questions or report adverse events through channels such as:

  • General consumer help lines
  • Patient support programs
  • Company medical information departments

However, for specific medical advice about their own condition and its treatment, patients should always consult their own health care provider, who will be more knowledgeable about the patient's individual circumstances.

Product Web sites

Some companies provide additional medicine information for patients online. However, patients should always consult their health care provider for specific medical or treatment advice.

Back to top

 

Disease management guides

These guides are provided to support patients who participate in programs designed to help control their disease. Topics often include:

  • Taking their medicines as prescribed (compliance)
  • Managing lifestyle factors
  • Learning how to monitor their condition
  • Knowing when to seek input from their health care team

Clinical trial information

The member companies of the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Industry Organization (BIO) have adopted voluntary principles that include being transparent about the clinical trials that they sponsor. The companies commit to submitting information to a public database, such as www.ClinicalTrials.gov, to help patients:

  • Find information about ongoing clinical studies for which they may be eligible
  • Including study description, recruitment information, study location, and contact information
  • View results—both positive and negative—for completed clinical trials of approved products
  • Including, at a minimum, study design, study population, outcomes, and serious or frequent adverse events

The clinical trial database—www.clinicalstudyresults.org—created by PhRMA in 2002 was phased out during 2011 due to the expansion and extensive use of government databases such as www.ClinicalTrials.gov.

Learn more about these organizations:

  • Visit PhRMA's Web site
  • Visit BIO's Web site

The International Federation of Pharmaceutical Manufacturers Associations (IFPMA)—on behalf of its member companies and associations—has created an Internet portal to provide a single point of entry to search a registry of comprehensive information about ongoing clinical studies as well as a database of results from completed studies conducted by the global pharmaceutical industry.

Learn more:

  • Enter the IFPMA Internet Portal
  • Visit IFPMA's Web site

Back to top

 

Adverse event reports

  • Patients may report their adverse event experiences directly to the manufacturers of their medicine. A toll-free telephone number is frequently included on packaging or in the printed information given to patients along with their medicines.
  • Pharmaceutical companies may also solicit and collect adverse event information from patients in the course of contacts related to patient support or product follow-up programs and in post-approval studies.

> Next:  Industry & Health Care Professionals
< Previous:  Regulatory Agencies & the Pharmaceutical Industry

Medicine Safety Education Home

2390963112001
 
Pharmaceutical Industry & Health Care Professionals

Partnering to Protect Patients:
The Pharmaceutical Industry & Health Care Professionals

Pharmaceutical companies and health care professionals work together to identify and manage possible safety issues both during the testing of new medicines as well as after medicines are approved by regulatory agencies for use by the public.

 

Designing and conducting clinical studies

When designing a clinical study program to test a potential medicine, pharmaceutical companies frequently work with independent consultants who are leading medical experts in the therapeutic area under investigation.

For large studies conducted at multiple sites, some of these experts may take on the role of:

  • Lead investigators
  • Independent members of Data Safety Monitoring Boards (DSMBs): These boards examine safety data from certain studies on major health outcomes—such as heart attack or cancer recurrence—both during the studies and at their conclusion. DSMBs provide scientific advice to the company sponsoring a given clinical study regarding safety concerns if a safety concern were to arise. If data suggest that changes would enhance patient safety—such as modifying a protocol or, in extreme cases, halting suspending or a clinical trial—a DSMB can recommend such an action.

Prior to and during clinical studies, the sponsoring pharmaceutical company provides extensive data on the known safety profile of the medicine being studied to the health care professionals serving as study investigators. The company also trains investigators to document and report adverse events, efficacy data, and other study-related information.

Back to top

 

Providing information about approved medicines

For approved medicines, companies make the professional prescribing information—or product labeling—available to all health care professionals through means such as product literature and product Web sites. Safety information from clinical studies and pharmacovigilance data may also be disseminated through:

  • Letters to health care professionals (for example, "Dear Health Care Professional" letters)
  • Peer-reviewed professional journal articles
  • Medical conferences
  • Online presentations
  • Product Web sites

When companies distribute product literature to clinicians and pharmacists, it is designed to contain a balanced presentation of a medicine's benefits and risks as well as approved instructions for that medicine's intended use.

Back to top

 

Reporting adverse events and other issues

Reports of adverse events, product defects, or suspected counterfeit products may be brought to the attention of the pharmaceutical company in several ways. For example, clinicians, pharmacists, or other health care professionals may:

  • Contact the manufacturer of a medicine directly
  • Alert the manufacturer's sales personnel during office visits
  • Alert the company's medical information department during a query

> Next:  Regulatory Agencies & Patients
< Previous:  Industry & Patients

Medicine Safety Education Home

2390963112001
 
Regulatory Agencies & Patients

Partnering to Protect Patients:
Regulatory Agencies & Patients

Medicine safety is a two-way street with regulatory agencies and patients both playing an active role.


Regulatory agencies such as the FDA or MHRA (the Medical and Healthcare products Regulatory Agency in the UK):

  • Maintain telephone information lines to answer consumers' questions about medicine safety or other product facts
  • Provide adverse event information concerning specific medicines or classes of medicines to consumers through fact sheets, print and online alerts, and news releases

    Visit the FDA's Index to Drug-Specific Information to view safety information for specific drugs

    View EMA's Find Medicine pages to see whether a specific medicine has an active safety alert, and to access a "public-friendly" assessment report and, if available, the patient-oriented Package Leaflet, usually included in Annex III.B of the Summary of Product Characteristics (SPC).

    Please consult your local regulatory agency for safety information about specific medicines prescribed in your country.

Patients may:

  • Report adverse events directly to regulatory agencies through programs such as the FDA's MedWatch system and telephone hotlines
  • Provide safety data to regulatory agencies in responses to health-related population surveys
  • Obtain information on ongoing interventional clinical trials as well as summary results from completed trials on public or government Web sites

    Visit the clinical trial database of the U.S. National Institutes of Health.
    Go to www.clinicaltrials.gov

    Access the International Federation of Pharmaceutical Manufacturers Associations (IFPMA) Internet Portal.
    Enter Portal

> Next:  Regulatory Agencies & Health Care Professionals
< Previous:  Industry & Health Care Professionals

Medicine Safety Education Home

2390963112001
 

Partnering to Protect Patients:
Regulatory Agencies & Health Care Professionals

Health care professionals and regulatory agencies work together to review and analyze data about medicines in testing and share information about approved medicines to help manage any potential risks.

 

Health care professionals:

  • May report adverse events in writing, verbally, or via Web sites to regulatory agencies such as:
  • FDA's MedWatch system (United States)
  • EMA's EudraVigilance system (Europe)
  • MHRA's Sentinel system (United Kingdom)
  • Serve as independent clinicians on regulatory agency advisory committees, reviewing and analyzing safety and efficacy data both for investigational and approved medicines. These committees provide scientific advice and make recommendations regarding:
  • Approval of medicines
  • The need for further testing
  • Safety data collection or analysis
  • Specific content of a product's professional prescribing information or patient information leaflet
  • Emerging safety issues or other matters

Regulatory agencies:

  • Maintain comprehensive databases of adverse event reports such as:
  • FDA's Adverse Event Reporting System (AERS)
  • EMA's EudraVigilance system (Europe)
  • MHRA's Sentinel system (U.K.)
  • PMDA's Perceive system (Japan)
  • May provide adverse event data to other initiatives such as the database of the World Health Organization's Collaborating Centre for International Drug Monitoring
  • May make data extracts from individual case safety reports freely available online for browsing or download
  • View U.S. FDA FOI AERS ICSR data extracts
  • View U.K. MHRA Yellow Card data extracts
  • Issue technical safety bulletins on specific emerging potential safety issues and maintain publicly accessible archives of such information. These are published in:

  • Newsletters—such as Morbidity and Mortality Weekly Reports (MMWR)
  • Fact sheets
  • Web sites
  • Advisory board reports
  • News releases—such as those sent out to announce "Dear Health Care Professional" letters

Back to top

> Next:  Health Care Professionals & Patients
< Previous:  Regulatory Agencies & Patients

Medicine Safety Education Home

2390963112001
 
Health Care Professionals & Patients

Partnering to Protect Patients:
Health Care Professionals & Patients

The partnership between a doctor—or other health care professionals—and a patient is critical to managing possible medicine safety issues. And open, honest communication is the key to a successful partnership.

 

Health care professionals help patients manage medicine risks by:

  • Helping them make informed decisions in selecting medicines with benefit-risk profiles that are appropriate for them as individuals
  • Counseling patients about possible side effects and how to manage them, should any occur
  • Responding to patients' specific safety concerns
  • Distributing patient educational materials designed to provide information on the proper use of medicines as well as specific side effects or related safety concerns

Patients can play an active role in medicine safety by:

  • Taking medicines as instructed
  • Keeping their health care team fully informed about their health and medication history
  • Reporting their adverse event experiences to the health care professionals treating them

< Previous:  Regulatory Agencies & Health Care Professionals

Medicine Safety Education Home

2390963112001
 

 

Printable Version
 
 

Close

Welcome to our Medicine Safety Web site. This site is designed to help you learn more about the science, processes, and people involved in the work of understanding the risks and benefits of medicines.

As part of the global health care community, pharmaceutical companies work with regulatory agencies, health care professionals, and patients to understand, as precisely as possible, the risks and benefits of each medicine we develop. Information about medicine safety begins to emerge in the research laboratory—and continues to evolve for as long as the medicine is prescribed to patients anywhere in the world. That’s why there are systems and processes in place at each step to help identify and communicate benefits and risks to everyone involved in making decisions about treatment.

Throughout this site, we will help you explore these processes as well as the science behind the research and development of prescription medicines. Look for the guide in each section of the site and press play for help in navigating through the information.

  • Video Host: Read what I'm saying

Resource Library

AskMe3 For Medicine Safety
Visit the Ask Me 3
For Medicine Safety page

Source URL: http://www.pfizer.com/health/medicine_safety/medicine_safety_education/health/medicine_safety/medicine_safety_education/health/medicine_safety/medicine_safety_education/safety_ddv_phase1_tab2?qt-medicine_safety_education=3